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Chapter 1 
Introduction to the thesis 
Colorectal cancer incidence and diagnosis 
Colorectal cancer is the third most common malignant neoplasm worldwide. The 
risk of colorectal cancer begins to increase at the age of 40 and rises sharply at 
the ages of 50 and 55; the risk doubles with each decade, and continues to rise 
until the age of 75- 80 years. 
Clinical manifestations vary according to the localization and the size of the 
tumor. Patients with tumors localized in the sigmoidal colon or rectum most often 
visit their physician because of altered stools with or without blood. Other 
complaints are ineffective urge to defecate or severe obstipation. Patients with 
more proximal tumors most often display iron deficiency anemia, whereas 
mechanical complaints, such as bowel obstruction or a palpable tumor mass 
develop in a later stage. 
The disease is generally diagnosed by means of colonoscopy, which offers the 
opportunity to take biopsies of the tumor. In case of (imminent) bowel obstruction 
an X-ray with a watery contrast medium is the safest option. For selected cases of 
rectal cancer magnetic resonance imaging has shown to be of great value. 
Treatment of localized colorectal cancer 
The treatment of localized colon cancer is surgery with or without chemotherapy. 
The treatment of localized rectal cancer is surgery with or without radiotherapy. 
Surgical resection is the only treatment which may lead to cure. Surgical skills 
and the type of procedure performed strongly influence prognosis. 
Furthermore, the tumor stage ( how deep did the tumor invade the bowel wall and 
did it spread to regional lymph nodes?) is a strong indicator of prognosis. In 
current practice the staging of the tumor does not suffice to separate the most 
agressive tumors from the others. However, this knowledge is of great importance 
for the design of the total treatment plan. Should the patient in addition to surgery 
be treated with adjuvant chemotherapy or in case of rectal cancer with irradiation? 
Such treatments mean a great burden to the patient and it would be of great 
benefit if they could be skipped. Therefore, we performed an in depth analysis to 
identify histological parameters with a clear impact on prognosis. 
10 
Radiotherapy is often applied to patients with rectal cancer, either as an adjuvant 
before or after surgery, or as primary therapy in case of irresectable cancer of the 
rectum. Adjacent small bowel loops located within the radiation portal may sustain 
late radiation damage, which is generally called radiation enteritis. Radiation 
enteritis may lead to bowel obstruction, bowel perforation, or untreatable diarrhea. 
As there were no guidelines how to approach such patients, we performed a 
retrospective study among patients who had been operated on because of 
complications due to radiation enteritis, in order to evaluate the surgical methods 
applied and to develop a proposal for a surgical protocol. 
Treatment of metastasized colorectal cancer 
In the past the treatment of metastasized colorectal cancer was chemotherapy or 
nothing. For a long time surgery was not considered to be useful in the treatment 
of these patients. In the Netherlands Cancer Institute in Amsterdam 
metastasectomy for isolated metastases was considered a valuable procedure, 
but scientific evidence was lacking. Therefore, we conducted a survey to evaluate 
the Netherlands' experience with this treatment modality to determine the results 
and to establish guidelines for this approach. 
From the sixties until the mid-nineties, the only chemotherapeutical agent 
available for the palliative treatment of patients with advanced colorectal cancer 
was 5-fluorouracil ( 5-FU). It was combined with a biomodulator, an agent which 
can enhance 5-FU-cytotoxicity. For a long time 5-FU-based palliative 
chemotherapy was regarded to be of little therapeutical value. There was only 
one small study in which was concluded that a modest improvement in survival 
could be obtained. Because of its great burden for patients, their family, their 
physicians and hospitals, we planned an analysis to determine the definite value 
of such chemotherapy. 
In this period, second line alternatives were not available for patients who 
progressed on 5-FU-based chemotherapy. It was hypothesized that modulator 
rotation, i.e. the replacement of the 5-FU-biomodulator by another, could 
overcome 5-FU-resistance. It was therefore important to get an idea of the 
results. Hence, we tested whether this approach led to clinical benefit. 
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Overall prognosis 
In general, the prognosis for patients with colorectal cancer is poor and treatment 
options are limited. It is therefore very important to obtain the best results from the 
available treatment modalities. In order to reach this goal, the treatment 
conditions should be optimized. In this context we studied the clinical relevance of 
tumor hypoxia. 
Tumor hypoxia results from a mixture of poor vascularization and anemia. It has 
been linked to neovascularization and a higher rate of locoregional and distant 
metastasis. Hence, we evaluated whether anemia prior to rectal cancer surgery 
worsened overall survival, irrespective of other well known prognostic factors. 
In later stages of colorectal cancer cancer-induced weight loss or cancer 
cachexia, defined as involuntary weight loss and tissue wasting, often occurs. 
With previous studies of others in mind, we postulated that tumor hypoxia is the 
drive to cancer cachexia. This hypothesis is based on the recognition that 
hypoxia, which occurs in most large tumors, leads to anaerobic dissimilation. This 
results in an increasing glucose demand, which urges the liver to increase its 
gluconeogenetic activity. From the moment when food uptake becomes the 
limiting factor, the liver will also dissimilate substrates , like fatty acids and amino 
acids, which originate from the structural components of body tissue. As a 
consequence, loss of body weight begins, the first step of cancer cachexia. This 
hypothesis has been tested in a murine cancer cachexia experiment in which was 




Outline of the thesis 
In this thesis we start with providing a review of colorectal cancer diagnosis, 
treatment and prognosis anno 2003 in chapter 3. 
In chapter 4 a case-control study is described in which was evaluated whether 
Dukes Β colorectal cancer patients with a high risk of recurrence could be 
identified by a histological evaluation according to the Jass criteria ( a new 
staging system for colorectal cancer, which included the tumoral growth pattern) 
and certain immunohistochemical colorings which had appeared of prognostic 
significance in earlier studies. Such high-risk patients may benefit from adjuvant 
chemotherapy, while their low-risk counterparts can be saved a troublesome 
treatment. 
The results of a retrospective cohort study of patients treated for late radiation 
enteritis in the Netherlands cancer Institute, which was performed to evaluate 
which surgical strategy offered the best longterm solution, are reported in chapter 
5. 
In chapter 6 the results of a national survey are provided, which was conducted to 
evaluate the feasibility and efficacy of pulmonary metastasectomy for isolated 
colorectal cancer metastases and to determine the indications for this method. 
In a retrospective analysis with matched historical controls we estimated the gain 
in survival reached by 5-fluorouracil-based palliative chemotherapy. The results of 
this analysis are described in chapter 7. 
The study described in chapter 8 was based on the hypothesis that modulator 
rotation, i.e. the replacement of the 5-FU-biomodulator by another, could 
overcome 5-FU-resistance. An overview of the patients wo had been treated 
according to this hypothesis in Nijmegen University Medical Center is given. 
In the study, which is described in chapter 9, we evaluated whether the longterm 
prognosis for rectal cancer patients was significantly influenced by preoperative 
anemia, irrespective of tumor stage, age and treatment. 
Current insights in the etiology and treatment of cancer cachexia are described in 
chapter 10. Based on a thorough review of the literature, we postulated that tumor 
hypoxia plays a central role in the development of cancer cachexia, which is 
explained in chapter 11. 
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In chapter 12 the results of a murine cancer cachexia experiment are published. 
In this experiment the relation between tumor size, tumor hypoxia and weight loss 
was evaluated. Furthermore, the effect of erythropoietin treatment on weight loss 
was assessed. 
Future perspectives concerning colorectal cancer treatment and research are 
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Abstract 
In the last two decades the prognosis of colorectal cancer has improved for two 
reasons: Firstly, the proportion of patients with localized disease has increased 
and treatment has been standardized. Secondly, new chemotherapeutic agents 
have led to a longer life expectancy for patients with advanced disease. In this 
review the current insights in disease etiology and treatment of localized and 
disseminated colorectal cancer are discussed. 
Epidemiology 
Colorectal cancer is the third most common malignant neoplasm worldwide1. The 
risk of colorectal cancer begins to increase at the age of 40 and rises sharply at 
the ages of 50 and 55; the risk doubles with each decade, and continues to rise 
exponentially. Efforts to identify causes have led to the hypothesis that 
adenomatous polyps are precursors for the vast majority of colorectal cancers2. 
Genetics, experimental and epidemiologic studies suggest that the development 
of colorectal cancer results from complex interactions between inherited 
susceptibility and environmental factors3"8. Heritable factors include familial 
polyposis colorectal cancer and hereditary non polyposis colorectal cancer. 
Inflammatory bowel disease is also related with a higher colorectal cancer risk. 
Dietary factors considered to increase colorectal cancer risk are high total fat 
intake and the consumption of meat and alcohol9"12. Dietary factors considered to 
decrease colorectal cancer risk are fiber and calcium13"15. The use of nonsteroidal 
anti-inflammatory drugs also appears to decrease colorectal cancer risk16. This is 
thought to be due to the the inhibition of cyclooxygenase-2 ( COX-2), an enzyme 
which indirectly induces resistance to apoptosis, systemic immunosuppression 
and tumor angiogenesis17. Ongoing clinical trials are currently testing the potential 
therapeutic role of COX-2-inhibitors in both prevention and treatment of different 
human cancers. 
Because of the the high incidence of colorectal cancer an effective screening 
program would be more than welcome. Faecal occult blood testing is a useful 
procedure if performed properly and several randomized controlled trials have 
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confirmed that a mortality reduction of 16% can be achieved18. However, the cost 
of the initial testing and the subsequent colonic assessment has not been 
subjected to a proper cost-benefit analysis and the performance of this test is no 
common practice in the Netherlands. 
Staging and prognostic features 
Up to now, only the Dukes classification ( and later modifications) - based on 
tumor extension and nodal involvement - has been implicated in therapeutical 
decision making19. Since 1932, this classification has been modified several 
times20,21. The latest classification - based on tumor extension, nodal involvement 
and presence of distant metastases (TNM-status)- has been formulated by the 
International Union against Cancer in cooperation with the American Joint 
Committee on Cancer. The Dukes classification is however still most often used 
in clinical practice. Its relation with more recent modifications and TNM-status is 
depicted in table 1. The reliability of tumor staging clearly depends on the number 
of lymph nodes recovered from the resection specimen. Several studies have 
shown that survival of Dukes Β colorectal cancer patients increases with the 
number of negative lymph nodes examined22"24. There is no communis opinio 
regarding the clinical relevance of micrometastases, and the results of the studies 
performed are conflicting25"28. 
The prognosis is strongly related with tumor stage and in the eightees 5-years 
survival percentages used to be about 82%, 73% and 40% for Dukes A, B, C 
tumors, consecutively29,30. Early diagnosis, adherence to general guidelines and 
new treatment strategies have resulted in improvement of these figures over the 
last two decades31"33. Several histological factors, such as thymidine 
Phosphorylase expression, mitotic index and vascular density appear to have 
independent prognostic significance34"41. There are also certain genetic mutations, 
such as inactivation of the P53-suppressor gene, which have shown a negative 
impact on prognosis42,43. 
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Table 1. Relation between TNM-status and older staging systems for colorectal cancer 
20 
Treatment of a primary colorectal carcinoma 
Current therapy for Dukes A and Β colon cancer consists of resection only. For 
Dukes C colon cancer 6 months of adjuvant chemotherapy is common practice as 
this reduces recurrence risk and improves survival. As the risk of local recurrence 
is much higher in rectal cancer, the efficacy of both adjuvant chemotherapy and 
adjuvant radiotherapy has been tested. Such studies used to be biased by the 
diversity of operation procedures. In the late nineties, due to its low rate of local 
recurrences, total mesorectal excision ( TME) became the standard procedure44" 
46. In a recent randomized controlled trial it has been shown that local recurrence 
risk can be lowered from 8.2 to 2.4 % by the addition of a short cycle of 
preoperative radiotherapy to the TME-procedure47. Adjuvant chemotherapy may 
eliminate distant micrometastases, enhance the local radiotherapy effect and 
improve overall survival. There are however no reports of prospective phase III 
trials which have tested the efficacy of both preoperative radiotherapy and 
adjuvant chemotherapy in patients who have undergone total mesorectal 
excision. 
A separate group is formed by patients with locally advanced rectal cancer. New 
promising approaches aimed at improving operability are intraoperative 
radiotherapy and radiotherapy in combination with hyperthermia. These 
procedures are however complicated and require the setting of a specialized 
center. Randomized prospective studies are lacking and only the former 
procedure has thus far shown a positive impact on clinical outcome48,49. 
Surgical palliation for advanced colorectal carcinoma 
Metastasectomy 
Surgical intervention is applied in selected patients with hepatic and/or pulmonary 
metastases. 
In case of isolated liver metastases the number, location and size of the 
metastases, the possibility to excise the metastases with a tumor-free margin of 
at least 1 cm and the volume of the remaining liver tissue play a deciding role in 
the choice whether or not to operate. The results of metastasectomy have never 
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been compared with the results of chemotherapy in a randomized prospective 
fashion. The former procedure results in a 5-years survival percentage of 25, 
which is much better than the outcome after chemotherapy50"54. However, one 
should realize that the extension of metastasis is usually smaller and the 
performance status better in patients who undergo metastasectomy than in 
patients who undergo systemic chemotherapy, which could partly explain the 
apparent superiority of metastasectomy. The extension of hepatic metastasis is a 
strong independent prognostic indicator of survival55. In the last decade the 
indication field for hepatic metastasectomy has widened for 2 reasons: 
Firstly, local ablation techniques, such as cryotherapy and radiofrequency 
ablation, have enabled the surgical treatment of patients with resectable and 
irresectable liver metastases56'71 The studies on cryotherapy have the longest 
follow up and a median survival of 26 to 32 months has been reported56'57,58,60,70. 
Both procedures differ in field of indication and complication rate; the maximum 
treatable diameter of liver metastases is considerably smaller for radiofrequency 
ablation than for cryotherapy. Radiofrequency ablation is however far less 
invasive and its complication rate lower. 
Secondly, a favourable chemotherapy response can render metastatic disease 
which was previously considered irresectable resectable72,73. 
In case of isolated pulmonary metastases surgical resection can also be very 
rewarding74"83. After previous pulmonary or hepatic metastasectomy the recurrent 
disease may again appear resectable and a second metastasectomy may result 
in a durable disease-free interval for a selected group of patients84. 
Regional chemotherapy 
For cases of localized irresectable disease the concept of regional chemotherapy 
seems attractive, as systemic toxicity is no longer a dose-limiting factor. Regional 
chemotherapy can be applied in case of hepatic or peritoneal metastases. 
Several investigators have tested the potential of cytoreductive surgery and 
intraperitoneal hyperthermic chemotherapy in patients with peritoneal metastases. 
The results appeared too poor to justify this therapy outside clinical trials85"87. 
Recently, Zoetmulder et al. have published very hopeful results: in a prospective 
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Phase Ill-study patients with colorectal cancer metastases confined to the 
peritoneal cavity were randomized to either palliative chemotherapy or a 
combination of operative cytoreduction, intraperitoneal hyperthermic 
chemotherapy and subsequent intravenous chemotherapy. The 2-years survival 
in the former group was 16% and in the latter group 43%, a significant 
difference88. 
In case of isolated irresectable liver metastases there are two ways to increase 
the chemotherapy dose beyond the threshold of serious systemic toxicity. Firstly, 
the liver can be connected to a perfusion system ( isolated liver perfusion). 
Secondly, one can deliver the chemotherapy through the hepatic artery ( hepatic 
artery infusion). For this procedure floxuridine is currently used as cytostatic 
agent. Whereas isolated liver perfusion is still considered to be in an experimental 
stage, hepatic artery infusion has become a standard procedure in quite a few 
surgical departments. The response rate after hepatic artery infusion has been 
shown to be significantly higher than the response rate after systemic 
chemotherapy89"94. A survival advantage has however only been found in two 
studies with a heterogeneous control-group of patients who received either 
supportive care or supportive care and systemic chemotherapy93,94. Relative 
disadvantages of hepatic artery infusion are procedure-specific complications, 
such as sclerosing cholangitis and chemical hepatitis, and the high cost of intra-
arterial pump implantation. 
Chemotherapeutical palliation for advanced colorectal carcinoma 
Fluorouracil ( 5-FU) 
For a long time 5-FU has been the most active single agent against advanced 
colorectal cancer and in the past decades research focussed on finding the most 
effective dosing regimen and on developing potent 5-FU-modulators, such as 
leucovorin and methotrexate. 
Bolus-5-FU in combination with the biomodulator leucovorin used to be standard 
first line treatment in both adjuvant and palliative setting. The Mayo Clinics 
regimen ( i.e 5-FU 425 mg/m2 and Leucovorin 20 mg/m2 , administered on 5 
consecutive days every 4 weeks) is the most often used treatment schedule. 
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Several studies have shown that treatment with the Mayo Clinics regimen 
prolongs median survival with about 3 to 6 months in patients with advanced 
colorectal cancer in comparison with supportive care only ( median survival 12 
versus 6 months)95"97 . Infusional 5-FU appears more effective in terms of 
response rate, but there is no difference between infusional and bolus-5-FU in 
terms of overall survival98,99. Some patients considered resistant to 5-FU-bolus 
therapy have shown responses to infusional 5-FU in second line100"102. 
Recently, oral fluoropyrimidines, such as capecitabine and UFT, have become 
available. Both drugs can be administered on an almost daytime basis and 
appear as effective as the MAYO-clinics regimen103'106. The convenience of 
staying at home during treatment in combination with a low toxicity profile ( 
comparable to infusional 5-FU) and equal efficacy has lead to the recognition of 
oral fluoropyrimidines as standard first-line treatment107. 
Novel drugs 
In the last few years two effective new drugs with a working mechanism which 
completely differs from the fluoropyrimidens have been introduced. They were 
initially introduced as second line alternatives. CPT-11 ( irinotecan), a 
topoisomerase l-inhibitor, has been shown to prolong survival in 5-FU-resistant 
patients in comparison with supportive care only and in comparison with 
infusional 5-FU108'109. Another promising new drug is oxaliplatin, a cisplatin 
analogue without renal toxicity. In combination with infusional 5-FU, it has shown 
a 25 % response rate in 5-FU-pretreated patients, whereas the response rate 
after oxaliplatin only appeared much poorer110"113. This suggests a synergistic 
effect between 5-FU and oxaliplatin. 
Meanwhile, CPT-11 and oxaliplatin have both emerged towards the frontline of 
palliative chemotherapy. In 2 randomized prospective trials the addition of CPT-
11 to either bolus-5-FU or infusional 5-FU and leucovorin led to a higher response 
rate and about 3 months median survival benefit114,115. Three studies have shown 
that oxaliplatin in combination with infusional 5-FU and leucovorin also leads to a 
considerable increase in response rate in comparison with bolus-5-FU and 
leucovorin, but a survival gain has not been found116"118. Goldberg et al. have 
recently reported a survival benefit of 4 months ( 18.6 versus 14.1 months) in 
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comparison with irinotecan, bolus-5-FU and leucovorin ( a.k.a. the Saltz-
regimen), but this difference might well be due to the fact, that oxaliplatin was not 
available as second line medication for the great majority of patients who had 
undergone the Saltz regimen119. All these first line therapy studies have 
undoubtedly been biased by the fact that second and third line alternatives were 
administered in an unstandardized and unrandomized fashion. There is no doubt 
about the efficacy of the fluoropyrimidines, irinotecan and oxaliplatin and the 
studies mentioned above have shown that these agents can add about 12 months 
to the median survival of patients with advanced colorectal cancer . The main 
issue is however in which order and in which combination these drugs should be 
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Abstract 
Background: The benefit of adjuvant chemotherapy appears to be limited for 
patients with Astler Coller B1/B2 colorectal cancer, but may be better in a 
subgroup of patients with a high relapse risk. In the present case-control analysis 
we evaluated whether patients with a high risk of hematogenous metastasis could 
be identified by means of a thorough histological and immunohistochemical 
examination of the resection specimens. 
Methods: A database was built for all patients treated in a general teaching 
hospital for colorectal cancer between 1985 and 1995. From this database all 
patients with an Astler Coller B1 or B2 tumor who had subsequently developed 
hematogenous metastases were taken as cases. For each case 3 matched 
controls ( age, Astler Coller stage, year of diagnosis) without metachronous 
metastases were selected. The resection specimens of cases and controls were 
blindly examined by two observers for: WHO classification; differentiation grade; 
growth pattern; lymphocytic, fibroblastic and eosinophilic reaction;angioinvasion; 
number of lymph nodes examined; expression of E-cadherin, vascular endothelial 
growth factor and thymidine Phosphorylase ( TP); P53; microvessel count. 
Results: Twenty two cases and 65 controls were included in the analysis. 
Tumor growth pattern and tumoral TP expression both independently contributed 
to relapse risk. With these 2 variables 4 subgroups could be identified with a 
relapse risk ranging from 0 to 42%. 
Conclusion: Tumor growth pattern and degree of TP expression both appear to 
be related to the relapse risk. Prospective trials should point out whether these 




Approximately 25% of the patients with Astler Coller BI or B2 colorectal cancer 
will die within 5 years due to recurrent disease1,2. An effective adjuvant 
chemotherapy-schedule would therefore be desirable. Unfortunately, the benefit 
of adjuvant chemotherapy has only been clearly shown in patients with node-
positive colorectal cancer. 
If one considers the group of patients with Astler Coller B1/B2 colorectal cancer, 
there are 3 important factors. Firstly, an unknown part of the tumors is probably 
understaged. Several studies have shown that at least 6 lymph nodes should be 
examined for reliable pathogical staging and a smaller number appears to be 
related with a poorer prognosis3"5. Secondly, lymph nodes which are considered 
negative at routine screening may appear to contain micrometastases. Studies on 
the relation between the presence of micrometastases and prognosis have 
however provided conflicting results and confirmation studies are required6"9. 
Thirdly, Astler Coller B1 and B2 tumors appear to differ in their tendency to 
metastasize and several histological and immunohistochemical variables have 
shown a relation with the prognosis in case of resected colorectal cancer. These 
variables are exponents of defective apoptosis ( P53 and DCC mutation), 
decreased cell-cell-adhesion ( E-cadherin) and neo-vascularization ( microvessel 
count, vascular endothelial growth factor and thymidine Phosphorylase). The 
present study adresses the question whether such variables can distinguish 
between patients with Astler Coller B1/B2 cancer who will eventually develop 
hematogenous metastases and those who will not. Such a prognostic model may 
enable the evaluation of the benefit of adjuvant chemotherapy in a subgroup with 
a high risk of metachronous metastasis. 
Patients and methods 
All patients who have been treated in the St. Joseph Hospital ( a general teaching 
hospital) for colorectal cancer between 1985 and 1995 have previously been 
entered in a database in cooperation with the Comprehensive Cancer Center 
South. This database included a subgroup of 295 patients with an Astler Coller BI 
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or B2 tumor stage. From this subgroup all patients who had eventually developed 
hematogenous metastases were taken as cases. For each case 3 controls were 
taken from the same subgroup. Cases and controls were matched for age ( + or -
3 years), year of diagnosis ( + or - 2 years) and tumor stage ( Astler Coller B1 or 
B2), but the controls were recurrence-free at the last date of follow up. For each 
control the follow up period was at least as long as the recurrence-free interval of 
the corresponding case. The resection specimens of all cases and controls have 
previously been examined in the same laboratory of pathology. 
The paraffin embedded tumor samples of all selected cases and controls were 
obtained for review. From an area with a high tumor cell density 4- micrometer-
sections were cut for haematoxylin eosin ( HE) staining and 
immunohistochemistry. Immunohistochemical staining was performed by means 
of commercially available mouse monoclonal antibodies for p53 ( clone BP53-12-
1, BioGenex laboratories, San Ramon, USA), e-cadherin ( clone HECD-1), 
vascular endothelial growth factor ( clone JH121, Neomarkers, Union City, USA) 
and thymidine Phosphorylase ( clone P-GF.44C, Neomarkers, Union City, USA) 
according to the guidelines of the supplier. Microvessels were visualized by 
means of rabbit anti-human Von Willebrand factor ( DAKO A/S, Glostrup, 
Danmark). The HE-slides of the tumor were independently and blindly examined 
by 2 observers for WHO histological classification, differentiation grade, growth 
pattern ( expanding vs diffuse infiltrative), grade of lymphocytic reaction, grade of 
eosinophilic reaction, grade of fibroblastic reaction, visible angio-invasion and the 
number of lymph nodes examined. Two different observers individually examined 
the immunohistochemical slides for: 
the presence of a p53-mutation ( = nuclear staining in at least 10% of the tumor 
cells); the percentage of tumor cells with membranous e-cadherin expression; 
the percentage of tumor cells with Vascular Endothelial Growth Factor ( VEGF) 
expression and the intensity of expression; the percentage of tumor cells with 
Thymidine Phosphorylase ( TP) expression and the intensity of expression. 
Microvessels were counted in a 200 χ magnification field which was supposed to 
have the highest microvessel density. This field had to be located at the invasive 
edge directly alongside tumor cells and clearly demarcated from ulcerative 
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regions. All staining cells and cell clusters with a maximum diameter of 50 
micrometer were regarded as microvessels. 
Statistical analysis 
For each immunohistochemical variable, except P53 and TP, the results were 
divided into fertiles. For each histological or immunohistochemical variable the 
relation with the risk of hematogenous metastasis was tested in a univariate 
manner. If a variable appeared to affect the risk of metastasis, we calculated the 
significance of this relation ( Chi-square test). The variables which showed some 
relation with the risk of metastasis ( p< 0.1) were entered in a stepwise logistic 
regression analysis in order to calculate their relative contribution to relapse risk. 
For each variable which showed a relation with relapse risk 20 random slides 
were blindly revised by two previously instructed observers in order to calculate 
the kappa value as an estimate of inter-observer variation. The statistical 
calculations were performed by means of the SPSS (version 6.1) computer 
program. 
Results 
Nineteen cases with stage B2 cancer and 6 patients with stage B1 cancer were 
included in the evaluation. At revision 3 cases appeared to have one or more 
tumor-positive lymph nodes and were excluded from the analysis. Sixty six 
controls had been selected for the remaining 22 cases. One of these controls 
appeared to have a node-positive tumor and was excluded. Overall, in 4 out of 91 
patients the database appeared to contain wrong tumor stage data, which is in 
accordance with a former publication on this subject10. Therefore, 87 patients 
were included in the analysis. 
In 28 patients the primary tumor was located in the rectum and in 59 patients the 
tumor was located in the colon. For the 22 cases the median duration of the 
interval between tumor resection and the appearance of hematogenous 
metastases was 17 ( range 8- 46) months. The metastases were located in the 
liver ( n= 10), the lungs ( n= 4), liver and lungs ( n= 7) or bone ( n= 1). For the 65 
controls the median duration of follow up was 86 ( 38-147) months. 
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Table 1 shows an overview of the tumor characteristics of cases and controls. 
The WHO-classification "mucinous adenocarcinoma", an expanding growth 
pattern and the absence of thymidine Phosphorylase expression appeared to be 
related with a lower metastasis risk. 
For the other variables tested no significant imbalance between cases and 
controls was found. WHO-classification, growth pattern and TP expression were 
entered in a stepwise logistic regression analysis (table 2). At step 1 the first 
variable mentioned lost its significance. The kappa values for tumoral growth 
pattern and TP expression were 0.62 and 0.67, respectively. 
Table 3 shows the frequency of hematogenous metastases according to growth 
pattern and thymidine Phosphorylase expression and illustrates the independent 
contribution of both variables to metastasis risk. 
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Location of tumor 
Rectum 
Colon 
Number of lymph nodes 
examined 
6 or less 

















% tumor cells with E-
cadherin expression 
70% or less 
71-95% 
more than 95% 
Hematogenous 
metastases 



















































% tumor cells with VEGF 
expression 
10% or less 
11-60% 






At least 37 per field 
38- 46 per field 
more than 46 per field 
Hematogenous 
metastases 

























Table 1. Tumor characteristics of patients with Astler Coller B1/B2 colorectal cancer who did and who 
did not develop hematogenous metastases according to a case-control study of 87 patients ( n.o.s.= 





WHO histological classification 








Table 2 The independent contribution of several histological factors to the risk of hematogenous 
metastasis in Astler Coller B1/B2 colorectal cancer according to a stepwise logistic regression analysis 
of Θ7 patients ( n= number of patients in the analysis) 
No TP expression 
Delineated growth pattern 
No TP expression 
Diffuse infiltrative growth pattern 
TP expression 
Delineated growth pattern 
TP expression 
Diffuse infiltrative growth pattern 
Hematogenous metastases 







Number of patients ( %) 
11 (17) 
6 ( 9 ) 
27 ( 42) 
21 ( 32) 
Table 3 Astler Coller B1/B2 colorectal cancer the frequency of hematogenous metastases according 
to tumor growth pattern and degree of thymidine Phosphorylase expression, results of a case-control 
study which included Θ7 patients ( TP= thymidine Phosphorylase) 
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Discussion 
The process of metastasis is a complex phenomenon in which genetic changes, 
angiogenesis and decreased cell-cell adhesion are supposed to be involved. In 
the last 15 years it has become possible to monitor such changes by means of 
immunohistochemistry. 
We evaluated whether patients with Astler Coller stage B1 or B2 colorectal cancer 
who had eventually developed hematogenous metastases could be distinguished 
from those who had remained disease-free by means of a thorough histological 
and immunohistochemical examination of the resection specimens. In our 
analysis two factors, tumor growth pattern and TP expression, independently 
contributed to the relapse risk. By means of these 2 variables we identified 4 
subgroups with a relapse risk which ranged from 0 to 42%. Both variables could 
be scored easily and we expect that the interobserver variation can be decreased 
by an increasing familiarity with these tests. In 1987 Jass and colleagues 
proposed a new staging system for colorectal cancer, which included the tumoral 
growth pattern11. They claimed that the prognostic value of their staging system 
was superior to the Dukes classification. Their system was however not broadly 
accepted, because the interobserver variation was considered too high12. Our 
results however confirm that tumoral growth pattern is a useful variable which 
deserves further study. 
Tumoral TP expression has been observed in a variety of malignancies, including 
colorectal cancer13"19. Reports on the prognostic value of TP expression in 
colorectal cancer are however conflicting. In a recent publication Saito et al. 
reported a tumoral expression rate of only 2%, as well as a relation between high 
stromal TP expression and a better survival20. Takebayashi et al. have however 
previously reported a relation between tumoral TP expression and a poorer 
survival, which is in agreement with our results. In case of other malignancies 
only tumoral TP expression has shown prognostic value13"17. Stromal TP is 
predominantly expressed by macrophages and it is as yet unknown how tumor 
cells and stroma interact in the production of TP. 
TP has been shown to be identical to platelet-derived endothelial cell growth 
factor and its angiogenic potential has been shown in vivo21"23. Therefore, its 
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relation with relapse risk is supposed to be mediated by neo-angiogenesis. We 
did however not find a relation between the degree of TP-expression and 
microvessel density and there are other studies which failed to show a 
relation20,24. This may be due to the fact that older microvasculature and 
neovasculature are both counted as microvessels. On the other hand, TP is a 
ubiquitous enzyme. It is present in all nucleated cells and catalyzes the 
conversion of thymine into thymidine, which is the first step in the salvage route 
by which thymidilate is synthesized. The degree of TP expression could therefore 
reflect the rate of DNA synthesis. Two studies strongly suggest that this is the 
case. In a study of 64 patients with Dukes Α-D colorectal cancer the apoptotic 
index was significantly lower in case of TP-expression and in another study of 154 
patients with a Dukes Β tumor a decreased apoptotic index appeared to be 
associated with a poorer survival25,26. The increased relapse risk in case of TP 
expression may therefore be due to more rapid tumor growth and neo-
angiogenesis. 
We did not find a relation between VEGF-expression or microvessel density and 
relapse risk. In a small study ( n= 27) by Takahashi et al. a higher intensity of 
VEGF-expression, as measured by an image analyzer, appeared to be related 
with a higher relapse risk27. According to a study by Kang et al., which 
encompassed 163 patients with Dukes Α-C colorectal cancer, those with a VEGF-
positive tumor ( i.e. VEGF-expression in more than 10 % of tumor cells) had a 
significantly poorer disease-free and overall survival28. Their cut-off point differed 
considerably from ours, but even after using this cut off point we failed to 
reproduce their findings. We did not find a relation between the microvessel count 
and relapse risk. In several cohort studies of colorectal cancer patients 
microvessel density has shown to be an independent prognosticator of overall 
survival28"31. For Astler Coller B1/B2 tumors a relation between microvessel 
density and relapse risk has been reported twice26,31. For the implication of the 
microvessel count in the decision-making concerning adjuvant chemotherapy a 
reproducible cut-off point should be available. Unfortunately this is not the case. 
The cut-off points found in the previously mentioned studies ranged from 16 to 75 
microvessels at a 200x magnification. 
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We did not find a relation between loss of E-cadherin expression and a higher 
relapse risk. Gofuku et al. have found a relation between loss of e-cadherin 
expression and a higher tumor stage, but a relation with relapse risk has not been 
reported before32. 
In our analysis Ρ 53 did not show any prognostic value and the results of previous 
publications are not convincing either. Two studies on patients with Dukes A-C 
colorectal cancer have shown a univariate relation between a P53 mutation and a 
poorer overall, whereas two other studies have not31,33"35. 
In conclusion, we have identified two tumor variables which appear to be of 
prognostic value in Astler Coller B1/B2 colorectal cancer. The usefulness of these 
variables should be tested by routine screening of the resection specimens of all 
patients entered in prospective randomized trials on adjuvant chemotherapy. 
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Summary 
We studied the records of 46 patients who had been operated on between 1974 
and 1990 in the Netherlands Cancer Institute because of complications due to 
late radiation damage of the small bowel. Data were collected on preoperative 
history, surgical intervention, postoperative complications and survival. By means 
of a Cox proportional hazards regression analysis we sought to identify factors 
that contributed to complication risk and survival. The following factors led to an 
increase in complication risk: hypalbuminemia, more than one laparotomy prior to 
irradiation and a short interval ( < 12 months) between irradiation and surgical 
intervention. The following factors related to a poorer survival: incomplete 
resection of the primary tumor and a short interval ( < 12 months) between 
irradiation and surgical intervention. The type of surgical intervention did not have 
cumulative prognostic value in relation to complication risk or survival. As patients 
who underwent resection differed considerably from patients who underwent a 
bypass-procedure, no conclusion could be drawn about the superiority of one 
technique over the other. We think that both types of intervention have their own 
field of indication. 
Introduction 
High dose radiotherapy is often used in the treatment of pelvic tumors. The 
maximum tolerated dose depends on the sensitivity of the small bowel within the 
radiation field. It is difficult to avoid exposure of the small bowel during pelvic 
irradiation, unless preventive measures have been taken. Terminal ileum loops 
tend to descend into the pouch of Douglas and into the space that has been left 
after resection of pelvic malignancies. Bowel mobility is often reduced by 
postoperative adhesions, which cause exposure of the same loops to each 
consecutive irradiation fraction. Acute radiation effects in the small bowel are 
generally reversible and only rarely lead to complications that require surgical 
intervention. Late radiation damage of the small bowel is characterized by 
progressive ischemia of the bowel wall. Endothelial cells are very sensitive to 
ionizing irradiation and histologic examination often reveals subendothelial 
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edema, intimai fibrosis and fibrin thrombi within mucosal, submucosal and serosal 
blood vessels1. These changes are irreversible. Carr et al. showed in a study of 
resected bowel specimens that blood perfusion was far below normal in the case 
of late radiation damage; areas around perforation had been totally deprived of 
their blood supply2. Additive damage to arterioles of the small intestine explains 
the higher incidence of late radiation damage among patients with diabetes or 
cardiovascular disease3. Five to 30% of the patients who undergo pelvic 
irradiation are reported to need operation for complications caused by late 
radiation damage of the small bowel: the incidence depends on several risk 
factors4"6. The most common indication for surgical intervention is bowel 
obstruction, less frequently bowel necrosis, perforation, fistula formation or 
gastrointestinal bleeding7"11. Peroperative findings usually include extensive 
adhesions, thickening and fibrosis of the bowel wall and mesentery and 
sometimes necrosis. It is often difficult to estimate the true extent of radiation-
induced bowel damage. Ideally the surgical intervention should solve the present 
complication, assure a swift recovery and prevent future complications. To reach 
these goals adhesiolysis only seldom suffices. Generally, either a resection or a 
bypass-procedure has to be performed. We evaluated the experience in the 
Netherlands Cancer Institute with surgical intervention for complications due to 
late radiation damage of the small bowel. The main goal was to identify factors 
that independently contribute to the outcome after surgical intervention, which 
could be helpful in pre- and postoperative decision making. 
Clinical data 
We reviewed the records of all patients who had undergone a laparotomy 
between 1974 and 1990 for complications caused by late radiation damage of the 
small bowel. Patients preoperatively diagnosed as having radiation damage of the 
small bowel, but whose complications proved to be caused by cancer recurrence, 
were excluded. Intraabdominal tumor recurrence was no exclusion criterion as 
long as the complications requiring surgical intervention were caused by radiation 
damage of the small bowel. We found 46 patients who met these criteria: 12 men 
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and 34 women with a median age of 57 years ( range 17 - 73 years) at the time 
of radiotherapy. 
Primary tumor treatment 
In 17 patients the primary tumor was located in the rectum or lower sigmoid colon, 
23 patients had a gynecologic tumor ( carcinoma of the uterine cervix in 15, 
carcinoma of the endometrium in 4, carcinoma of the ovary in 3 and carcinoma of 
the Fallopian tube in 1), three patients had a urologie tumor and 3 patients had a 
tumor of mesenchymal origin. Thirty eight patients had received radiotherapy 
following tumor resection. In 16 cases the resection had been complete and in 22 
cases the resection had not been complete. For eight patients the treatment 
consisted of radiotherapy only, 12 patients had received a combination of 
brachytherapy and external beam radiotherapy and one patient had only received 
brachytherapy. In most patients the target volume of irradiation comprised the 
primary tumor area and the regional lymph nodes within the pelvis. In 5 patients 
the radiation portal was larger, including the periaortal nodes. No data were 
available on the volume of irradiated small bowel or the cumulative dose it 
received. The median normalized total dose, calculated for external beam 
irradiation was 42.5 gray (range 20- 66 Gy).12 
Interval and clinical presentation of small bowel damage 
The median duration of the interval between the last radiotherapy session and the 
surgical intervention was 9 months ( range 1 - 269 months). Forty one patients 
presented with small bowel obstruction, three with overt small bowel perforation 
and two with enteric fistulas. No patients presented with gastrointestinal bleeding. 
Anemia with hemoglobin values below 7 mmol/L was found in 12 patients and 12 
patients had a serum albumen concentration below 35 gram/L. 
Findings at laparotomy and type of intervention 
All patients underwent a midline laparotomy. Extensive adhesions were found in 
almost all cases. We were not able to quantify the extent of adhesions and the 
thoroughness of adhesiolysis. In six patients intra-abdominal tumor recurrence 
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was found, as well as radiation damage of the small bowel. Pathologic small 
bowel loops were resected in 27 patients ( table 1). 
Primary tumor 
Rectosigmoid (n= 17) 
Gynecological tract ( n= 22) 
Other ( n= 6) 
Tumor recurrence in the abdomen 
at the time of surgical intervention 
Yes ( n= 6) 
No ( n= 39) 
Brachytherapy 
Yes(n=12) 
No ( n= 33) 
Symptomatic radiation damage in 
neighbouring mtrapelvic organs at 
the time of surgical intervention 
Yes ( n= 22) 































2 ( 9 ) 
Table 1 Type of surgical intervention according to several oncologic and radiotherapeutic factors 
In 12 patients bypasses were made and in 6 patients only adhesiolysis was 
carried out. In one patient only an ileostomy was made. So, bowel anastomoses 
were made in 39 patients. Thirteen anastomoses were made between two small 
bowel loops, 13 anastomoses were made between small bowel and ascending 




In 11 of 46 patients severe intra-abdominal complications developed within one 
month after surgical intervention. Complications were small bowel perforation ( n= 
7), ureteric leakage ( n= 1) and persistent small bowel obstruction. Reintervention 
was necessary in nine cases. Small bowel perforation presented as peritonitis or 
as small bowel fistulas. The cause of perforation was evident anastomotic 
leakage in one patient and anastomotic leakage was likely in four patients. In two 
patients the perforation had occurred in other bowel loops, most likely as a result 
of trauma during adhesiolysis. Therefore, we assume that five out of 39 
anastomoses have leaked. The leakage rate was three out of 13 for anastomoses 
between small bowel and ascending colon and two out of 13 for anastomoses 
between two small bowel loops. No leakage occurred after the formation of 
anastomoses between small bowel and transverse colon. All patients survived at 
least one month after operation. Late intra-abdominal complications were small 
bowel stenosis ( n= 8), fistula formation ( n= 3) and short bowel syndrome ( n= 3). 
Methods 
By means of a Cox proportional hazards regression analysis we calculated the 
independent contribution of several variables to the risk to develop intra-
abdominal complications and to survival. Starting point was the date of enteritis 
intervention. Primary endpoints were complication-free interval and survival. The 
following variables were included in the analysis. 
Patient factors: sex, age. Primary tumor treatment factors: type of tumor, 
complete vs incomplete resection, number of laparotomies prior to radiotherapy ( 
one or less vs more than one), normalized total dose for external irradiation, 
brachytherapy ( yes vs no). Interval between radiotherapy and date of surgical 
intervention·^ 12 months or less vs more than 12 months). Type of small bowel 
complication: obstruction, perforation, fistula. Preoperative factors: anemia, ( 
hemoglobin concentration below 7 mmol/L), hypalbuminemia ( serum albumen 
concentration below 35 gram/L). Findings at laparotomy: extensive adhesions or 
not, perioperative iatrogenic small bowel perforations, bypass vs resection, length 
of resected or bypassed small bowel segment ( < 0.5 metre vs 0.5-1.0 metre vs > 
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1.0 metre), type of anastomosis ( small bowel- small bowel, small bowel-
ascending colon, small bowel- transverse colon). 
Only factors that showed some relation to complication rate and survival in the 
univariant analysis were included in the regression model. The programs IL and 
2L of BMDP-PC90 were used for the calculations. 
Results 
Complication risk ( see table 2) 
Univariantly ( step 0) the complication risk decreased when the interval between 
radiotherapy and surgical intervention became larger. The risk increased in case 
of hypalbuminemia prior to operation. When we controlled for the interval between 
radiotherapy and surgical intervention ( step 1) a larger number of laparotomies 
prior to radiotherapy also contributed to an increased risk. 
Variable 
Maximum number of patients 
Serum albumen concentration 
Interval between radiotherapy 
and surgical intervention 
Number of laparotomies prior 
to radiotherapy 






















Table 2. Factors independently contributing to complication risk after surgical intervention; P-values of 
stepwise PH-regression analysis ( NS= not significant). 
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None of the other factors tested showed a relation with complication risk. When 
we controlled for interval and number of laparotomies ( step 2a), the influence of 
the serum albumen concentration lost its significance. However, the number of 
laparotomies lost its significance when we contolled for both serum albumen 
concentration and interval ( step 2b). 
The interval between radiotherapy and date of surgical intervention remained 
significant in both situations. Either interval and serum albumen concentration or 
interval and number of laparotomies have cumulative prognostic value. 
Survival ( see table 3) 
Univariantly ( step 0) patients who had undergone a complete resection of their 
primary tumor survived longer, as well as patients who had received a lower 
normalized total irradiation dose. Patients with a longer interval between 
radiotherapy and surgical intervention survived longer. 
Variable 
Maximum number of patients 
Complete vs incomplete resection 
of primary tumor 
Normalized total dose 
Interval between radiotherapy and 
surgical intervention 

















Table 3. Factors independently relating to survival after surgical intervention; P-values of a stepwise 
PH-regression analysis( NS= not significant). 
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None of the other factors tested showed a relation with survival. Multivariantly ( 
steps 1 and 2) the influence of the normalized total irradiation dose became 
insignificant. Interval and complete vs incomplete resection of the primary tumor 
have cumulative prognostic value. 
Discussion 
Severe complications due to late radiation damage of the small bowel pose a 
difficult problem. We evaluated our experience with the surgical treatment of 
these complications. It is obvious that many factors contribute to the pathology of 
late radiation damage of the small bowel, its clinical presentation and the outcome 
after eventual surgery. By means of a regression analysis we tried to determine 
factors that contribute independently to complication risk and survival after 
surgical intervention. 
A shorter interval between radiotherapy and surgical intervention related to a 
higher complication risk. This is likely to be an expression of more extensive 
damage to the microvasculature of the small bowel, resulting in a faster 
progression of tissue ischemia and the development of more serious 
complications in an earlier stage. Patients who had undergone a complete 
resection of their primary tumor survived longer, which stresses that tumor 
recurrence had an important impact on survival in our patients. Patients with a 
longer interval between radiotherapy and surgical intervention survived longer. 
This could be explained by our finding that they had fewer postoperative 
complications and consequently recovered better. Otherwise, a selection bias 
may be involved, as the risk of death due to cancer decreases after a longer 
recurrence-free interval. 
In our statistical analysis either the preoperative serum albumen concentration or 
the number of laparotomies prior to irradiation had cumulative prognostic value 
with respect to complication risk. In reality, both findings could be true. A low 
serum albumen concentration reflects in general a poor nutritional and clinical 
condition, which is likely to slow down postoperative recovery. A higher number of 
laparotomies generally leads to an increase in extent and severity of adhesions. 
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Because of decreased bowel mobility certain loops will be overexposed to 
irradiation, which may lead to more serious damage and consequently an 
increased complication risk. Fischer et al. have also reported a less favourable 
prognosis for patients who had undergone pre-irradiation laparotomies13. 
In our patients we found no leakage among anastomoses between small bowel 
and transverse colon, which is in agreement with the findings of Galland and 
Schofield14"16. An anastomosis with an unirradiated distal loop will have better 
healing properties than an anastomosis between two irradiated loops. The 
transverse colon is almost always located outside the radiation portal which is 
used for pelvic irradiation, whereas ileum and ascending colon are often located 
within2. 
The type of surgical intervention did not influence the complication risk. Similar 
results have been reported by other authors17"19. From our data ( table 1) it is 
obvious that we selected different groups of patients for bypass and for resection. 
Resection was favoured in cases in which adhesiolysis was technically easy, in 
cases in which the extent of visible bowel damage was limited and in case of 
perforation or fistula. In our material this occurred most often in case of a 
gynecological tumor, after combination of brachytherapy and external beam 
irradiation and if no intra-abdominal tumor was present. Bypass was favoured for 
patients in whom no sufficient adhesiolysis could be performed and if long, but 
vital bowel segments were involved. In our material this was most often the case 
in patients with non-gynecological tumors and if intraabdominal tumor recurrence 
was present. 
Conclusions 
This analysis has all the limitations of a retrospective study with a small sample 
size. Factors that independently contribute to a lesser extent to complication risk 
and survival may have remained undetected in our multivariate analysis. In spite 
of these limitations we think that some of our findings can be translated into useful 
guidelines for surgical intervention. 
Patients with multiple pre-irradiation laparotomies and a short interval between 
irradiation and surgical intervention are especially at risk for postoperative 
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complications and require special care. It is important to diagnose late radiation 
damage in an early stage. This may prevent situations in which acute operations 
have to be performed on malnourished patients. If the situation allows this, it 
seems worthwhile to take time to improve the patients nutritional status prior to 
operation. Hypalbuminemia does however not always reflect the patients 
nutritional status. It may also reflect a negative acute phase reaction due to more 
serious radiation-induced bowel damage. 
Surgery for radiation damage of the small bowel should always be performed with 
the greatest care. The type of intervention performed has to depend on the extent 
of adhesions and the severity of the small bowel damage. In case of severe 
damage in a relatively small segment resection is preferred. In case of extensive 
adhesions within the pelvis, bypass may be preferrable, especially if tumor 
recurrence is suspected. Otherwise, there is no evidence that either technique is 
superior. If an anastomosis has to be made after resection or as a part of a 
bypass-procedure, we strongly feel that at least one end of the anastomosis 
should consist of unirradiated bowel. In practice, an anstomosis between ileum 
and transverse colon meets this demand and has proven to be very safe. 
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Abstract 
Study objective: To develop selection criteria for pulmonary metastasectomy 
in patients with metastases of colorectal cancer confined to the lungs. 
Design: A retrospective study 
Setting: Medical records of all patients operated on for the condition in the 
Netherlands in the period 1982 to 1992 ( n= 38). 
Intervention: Evaluation by means of Cox's proportional hazards regression 
analysis of factors, which might relate to postthoracotomy disease-free survival 
and/or postthoracotomy survival. 
Measurements and results: The 5-years disease-free survival was 31% and 
the overall 5-years survival was 43% ( Kaplan Meier). Multivariately, a number of 
three or fewer metastases ( p= 0.012) and a short delay between detection of 
pulmonary metastases and resection ( p= 0.05) related to a longer 
postthoracotomy disease-free survival. A longer interval between resection of the 
primary tumor and detection of lung metastases related to a longer 
postthoracotomy survival ( p= 0.021). 
Conclusions: Patients with three or less pulmonary metastases of colorectal 
origin may benefit from resection; once metastases have been detected, 
resection should not be postponed. 
Introduction 
The results of treatment for metastatic colorectal cancer are disappointing. 
Chemotherapy will result in only partial responses in a minority of patients and 
complete responses are rare and shortlived1. In an autopsy study, 10% of patients 
with a colorectal carcinoma were found to have lung metastases and 1% of 
patients had isolated lung metastases ( i.e. confined to the lungs only)2. In theory, 
these patients might have benefitted from metastasectomy. Only a small number 
of patients with isolated lung metastases are subjected to resection 
therapy.Selection criteria commonly used are the number of metastases, the 
interval since primary treatment and the general condition of the patient. Several 
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retrospective studies have shown that patients with isolated pulmonary 
metastases benefit from resection. Five-years survival rates of 9 to 57% have 
been reported3"12. These published results are exceptionally good when 
compared with the outcome after chemotherapy in metastatic colorectal cancer. 
However, the number of cases reported in the literature is very small. This 
suggests that most authors have used very strict selection criteria for 
metastasectomy or that only a selection of cases have been reported, which may 
introduce a selection bias. In the Netherlands a nationwide database for 
pathology ( PALGA) is operational. With help of PALGA we collected information 
on all patients who had undergone pulmonary resections for metastases of 
colorectal origin in the Netherlands in a 10-years period. The data were analyzed 
to define factors that might be helpful in the selection of patients for operation. 
Materials and methods 
Data collection 
With assistance of the national database for pathology in The Netherlands ( 
PALGA) we identified 15 hospitals where resection for pulmonary metastases of 
colorectal origin had been performed in the period between 1982 and 1992. 
Because of privacy laws in The Netherlands PALGA does not contain the names 
of patients concerned, but only an identification number and the name of the 
surgeon responsible for the patient. Using this information, 15 surgeons were 
identified who had performed pulmonary resections of metastases of colorectal 
origin in the study period. They were asked to provide data on the patients under 
their care. Twelve of 15 surgeons responded and provided information on 38 
patients. Cases were included only if the histologic features of the pulmonary 
metastasis were compatible with the histologic features of the primary colorectal 
cancer. 
Study design 
End points of this study were the time between pulmonary metastasectomy and 
tumor recurrence ( postthoracotomy disease-free survival) and the time between 
metastasectomy and death ( postthoracotomy survival). For the following 
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variables we tested whether they related to postthoracotomy disease-free survival 
and/or overall survival: sex; site of primary tumor ( colon; proximal two thirds of 
rectum; distal one third of rectum); Astler Coller stage (A, B1, B2, C1, C2, D); 
interval between resection of the primary tumor and detection of lung metastases; 
resection of liver metastases prior to pulmonary metastasectomy; delay between 
detection of lung metastases and metastasectomy; age at the time of pulmonary 
metastasectomy; number of metastases resected ( 1; 2-3; 4 or more); surgical 
procedure confined to one lung ( wedge excisions vs lobectomy with or without 
wedge excisions vs pneumonectomy) or both lungs; length of hospital stay after 
metastasectomy. 
Results 
The study population consisted of 38 patients who had been operated on in 12 
hospitals. There were 24 men and 14 women. 
Primary tumor 
In 14 patients the primary tumor site was the colon, in 15 the proximal two thirds 
of the rectum and in 9 the distal one third of the rectum. The Astler Coller stage of 
the primary tumor was A or B1 in 5 patients, B2 in 15 patients, C1 or C2 in 16 and 
D in 2 patients. 
Interval between primary tumor treatment and detection of lung metastases 
The median duration of the interval between resection of the primary tumor and 
detection of lung metastases was 27 months ( range 1 to 87 months). Five 
patients had previously been operated on because of hepatic metastases; later 
they presented with lung metastases that were in turn resected. In the other 33 
patients lung metastases were the first site of recurrence. 
Pulmonary metastasectomy 
In all cases computed tomography ( CT) of the chest had been performed before 
pulmonary metastasectomy. In 31 cases the liver had been visualized, either by 
ultrasonography or by CT. Liver metastases were not found in either of these 
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patients. In 22 patients operation followed within one month after detection of the 
lung metastases. In 16 a delay of more than one month ( range 2 to 51 months) 
was recorded. The median age at the time of pulmonary metastasectomy was 64 
years ( range 29- 77 years). During surgery signs of mediastinal or pleural spread 
were not seen. In 22 patients 1 metastasis was resected, in 10 patients 2 or 3 
metastases were resected and in 6 patients 4 or more metastases were resected. 
In 33 patients the metastases were confined to one lung; 14 of these patients 
underwent only wedge excisions and the other 19 patients underwent a 
lobectomy with or without wedge excisions. Pneumonectomies were not 
performed. In 5 patients metastases were found in both lungs, which necessitated 
multiple bilateral wedge excisions. All resection specimens had tumor-free 
margins. There were no postoperative deaths. The median duration of hospital 
stay was 13 days ( range 6 to 37 days). None of the patients included in this study 
received either adjuvant radiotherapy or adjuvant chemotherapy in the 
postoperative period. 
Postthoracotomv disease-free survival 
Tumor recurrence was observed in 20 patients. In 5 cases the site of first 
recurrence was the lung; in all these cases recurrences were found either on the 
site of the previous thoracotomy or bilateral. In three cases the site of first 
recurrence was the liver. In 2 of these 3 cases the liver had been visualized by 
ultrasonography or CT before pulmonary metastasectomy and no metastases had 
been found. One patient presented with local recurrence at the site of the bowel 
anastomosis and 11 patients presented with metastases elsewhere. The 5-years 
disease-free survival after pulmonary metastasectomy was 31% ( figure 1). 
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Figure 1. Disease-free interval after pulmonary metastasectomy all patients ( n= 3Θ). 
A regression analysis was carried out to identify variables that related to the 
postthoracotomy disease-free survival ( table 1). Univariately, only the number of 
pulmonary metastases showed a significant relation with the disease-free interval 
( figure 2). For patients with 3 or less pulmonary metastases the outcome after 
metastasectomy was significantly better than for patients with 4 or more 
metastases ( p= 0.036). The interval between treatment of the primary tumor and 
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Table 1. Relation between different variables and postthoracotomy disease-free survival as calculated 
by means of a stepwise regression analysis. 
When we adjusted for number of metastases ( step 1) the delay between 
detection of pulmonary metastases and resection had borderline significance; 
patients who had been operated on within one month did better than patients with 
a delay of more than one month ( p= 0.05). Within the latter group were 2 patients 
with an exceptionally long period of observation ( 15 and 51 months). No other 
variables showed a relation with postthoracotomy disease-free survival ( step 2). 
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FIGURE 2. Relation between the number of pulmonary metasta­
ses resected and postthoracotomy disease-free interval. Patients 
with three or less metastases did significantly better than patients 
with four or more metastases (p=0.036) 
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Figure 3. Survival after pulmonary metastasectomy all patients ( n= 38) 
A regression analysis was carried out to identify factors relating to 
postthoracotomy survival ( table 2). Univariately, an age of more than 64 years at 
the time of metastasectomy ( p= 0.043), a shorter interval between resection of 
the primary tumor and detection of lung metastases ( p= 0.021) and a longer stay 
in the hospital after metastasectomy ( p= 0.034) related to a poorer 
postthoractomy survival. 
When we adjusted for the interval between resection of the primary tumor and 
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Table 2 Relation between different variables and postthoracotomy survival as calculated by means of 
a stepwise regression analysis A longer interval between treatment for the primary tumor and 
detection of lung metastases related to a better survival ( p= 0 021 ) 
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Figure 4 shows the influence of the interval between resection of the primary 
tumor and detection of lung metastases on survival. At 2 years of follow up 51% 
of patients with an interval shorter than 24 months were alive, whereas no deaths 
had occurred among patients with an interval of at least 36 months. 
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No other factors were found to be related to postthoracotomy survival; this 
includes the number of metastases resected. 
Discussion 
Our study bears all the disadvantages of a retrospective analysis in a small 
population. These data however represent the almost complete experience of 
pulmonary metastasectomy for colorectal cancer metastases in the Netherlands 
in a 10-years period and gives as such valuable information. The national 
database of pathology in The Netherlands ( PALGA) registers almost all 
pathologic findings of operations performed in the Netherlands since 1983. In the 
period between 1982 and 1992 approximately 70.000 patients have been treated 
for colorectal cancer and 35.000 have died of this disease. Of these 35.000 
patients 350 could be expected to have developed one or more isolated 
pulmonary metastases2. Although we assume to have collected data on most of 
the patients treated within this period, we found only 38 patients who had actually 
undergone resection therapy. It appears that only a minority of patients with 
isolated lung metastases of colorectal origin have undergone resection. Several 
explanations are possible. It may be that most patients presented with many or 
irresectable metastases and were therefore considered inoperable. However, it is 
also possible that metastasectomy was simply not considered. The fact that the 
reported metastasectomies have taken place in a minority of the Dutch hospitals 
suggests that the last assumption is probably true. 
Nowadays, pulmonary metastasectomy is a safe surgical procedure with a low 
morbidity and a very low mortality. This is confirmed by our series in which no 
postoperative deaths were recorded. Most metastasectomies in this series have 
been done by means of posterolateral thoracotomy. Only a few patients have 
undergone sternotomy. We are not able to comment on the relative benefit of 
either approach. Proponents of sternotomy emphasize the advantage of the 
bilateral exploration, which might show small metastases not visible on CT scan. 
Our finding that recurrences within the lung were always on the same side as the 
original metastases and had apparently been missed during operation does not 
support this argument. However, sternotomy is simple and usually causes less 
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pain after operation compared with posterolateral thoracotomy. In case of bilateral 
metastases sternotomy has the obvious advantage of reducing surgery to one 
operation. Resection of metastases in the posterobasal segments, especially on 
the left side, can be difficult in case of sternotomy. 
Longterm survival of patients with lung metastases of colorectal origin is rare and 
there is little doubt in our mind that the good results in our study population ( i.e. 5 
years postthoractomy disease-free survival of 31% and 5 years postthoractomy 
survival of 43%) were directly related to the surgical intervention. As these data 
are from a nationwide survey, these results have not been influenced by a 
publication bias. In this study we looked for factors that contributed to 
postthoracotomy disease-free and overall survival. Age, sex, site of primary 
tumor and Astler Coller stage did not relate to disease free or overall survival, 
which is in accordance with other series3,5,13. The type of surgical procedure did 
not relate to disease-free or overall survival either. 
The postthoracotomy disease-free survival was significantly influenced by the 
number of metastases and the delay between detection of metastases and 
resection. In contrast, survival was influenced only by the interval between 
resection of the primary tumor and resection of the lung metastases. As 
recurrence after metastasectomy almost unevitably leads to death, we assume 
that the difference between factors influencing postthoracotomy disease-free 
survival and factors influencing overall survival will disappear with longer follow 
up. The fact that most resections of four or more metastases have been 
performed in recent years may especially have influenced the results. We 
conclude that both number of pulmonary metastases and interval between 
resection of the primary tumor and detection of the lung metastases relate to the 
outcome after metastasectomy. 
The purpose of our analysis was to identify factors that could be used for the 
selection of patients for metastasectomy. The number of pulmonary metastases 
provides a clear indication; all patients who had undergone resection of 4 or more 
metastases showed tumor recurrence within 16 months, whereas 50% of patients 
with less than 4 metastases were still disease-free 5 years after metastasectomy. 
We conclude that patients with 3 or less pulmonary metastases will probably 
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benefit from operation and should be offered this option. Our data do not exclude 
a benefit for patients with 4 or more metastases in terms of a longer survival. To 
prove such a benefit a randomized trial comparing metastasectomy with no 
metastasectomy would be needed. Outside such a study, resection of 4 or more 
metastases can at present not be recommended. It is obvious that a second 
primary malignancy should always be considered in case of a solitary lesion. 
The interval between resection of the primary tumor and detection of lung 
metastases appears to be a less useful selection criterion, as there were also 
longterm survivors among the patients with a short interval. Apparently, a long 
interval between treatment of the primary tumor and the detection of lung 
metastases is an expression of slow growth. These patients can be expected to 
live longer, irrespective of the metastasectomy. Patients who had previously 
undergone resection of liver metastases did not show a poorer postthoracotomy 
disease-free or overall survival. In our opinion, this group should be treated as if 
the lung metastases were the first site of recurrence. 
The finding that the delay between detection of pulmonary metastases and 
resection adversely influenced outcome is very interesting. This observation may 
be partly due to a lead time bias: if patients die irrespective of the 
metastasectomy, the survival after thoracotomy is shorter if the thoracotomy is 
performed later. However, this does not explain a significant difference in 5-years 
survival. It can only be explained if the delay allows further spread of tumor cells 
from the metastases. Whatever the explanation, our findings certainly do not 
support the use of an observation period in the management of pulmonary 
metastases from colorectal origin. 
Conclusions 
The findings of this study point out that resection of isolated lung metastases from 
colorectal origin should always be considered. Patients with up to 3 isolated 
pulmonary metastases are expected to benefit from metastasectomy. 
Metastasectomy is indicated in these patients irrespective of the interval between 
treatment of the primary colorectal cancer and the development of lung 
metastases. A period of observation does not appear to be useful. 
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Abstract 
Background: An analysis was performed to evaluate whether bolus chemotherapy 
with 5-fluorouracil (5-FU) and leucovorin (LV) improves survival for patients with 
advanced colorectal cancer (ACC). 
Patients and methods: Two groups of patients were selected from a database 
which included all patients with colorectal cancer treated in our hospital since 
1984. The first group consisted of all patients with irresectable metastases 
diagnosed between January 1984 and December 1989, who had a performance 
status of 0 or 1 and were younger than 76 years old. The second group consisted 
of all patients with irresectable metastases - younger than 76 years old and with 
a performance status of 0 or 1- who were started on chemotherapy between 
January 1994 and December 1997. In the first period chemotherapy was never 
given and in the second period chemotherapy was given to all motivated patients. 
None of the patients had received a previous metastasectomy or isolated liver 
perfusion. For chemotherapy, age, location of the metastases, type of surgical 
intervention for the primary tumor, Hemoglobin, Lactate Dehydrogenase and 
Carcinoembryonic Antigen concentration we evaluated the relation with survival. 
Variables which showed a significant relation with survival in the univariant 
analysis (logrank test, p< 0.05) were entered in a proportional hazards regression 
analysis. 
Results: In the univariant analysis chemotherapy and location of metastases 
showed a significant relation with survival. The median survival was 11 months for 
patients who had received chemotherapy and 8 months for untreated patients (p= 
0.009). Chemotherapy and location of metastases both retained their significance 
in a proportional hazards regression analysis. 
Conclusion: In our study group chemotherapy added 3 months to the median life 
expectancy for patients with ACC. 
Introduction 
The prognosis for patients with advanced colorectal cancer (ACC) is poor. Before 
the beginning of the last decade chemotherapy for ACC was merely regarded as 
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a means to decrease or stabilize the tumor load, which could lead to 
postponement of complaints and an improved quality of life. In the last decade, 3 
randomized prospective studies which comprised a total number of 240 patients 
have shown a survival advantage for patients treated with 5-Fluorouracil-based 
chemotherapy in comparison with patients who had received best supportive 
care13. This finding was however only significant in one of these 3 studies2. In 
spite of the limited amount of data, this finding was considered significant enough 
to abandon the no-treatment arm in all following Phase Ill-studies. Meanwhile, 
these studies have revealed a lot of knowledge about optimal 5-FU dosing 
schedules and novel agents, such as Trimetrexate and CPT-11. 
At present, the first-line chemotherapeutic regimen applied outside clinical trials 
usually consists of 5-fluorouracil (5-FU) with one or more biomodulators, such as 
Leucovorin (LV) or methotrexate. The question remains how many months such 
therapy may add to the median life expectancy. Since 1993, it is general policy in 
our hospital to recommend chemotherapy to all patients with ACC. The first-line 
chemotherapy regimen consists of bolus injections with 5-FU (425mg/m2) and LV 
(20mg/m2) which are given on an outpatient basis on day 1-5 and from day 29 
once weekly. The present paper adresses the question whether this treatment 
significantly prolongs life based on a comparison with untreated controls. 
Materials and methods 
The names of all patients who had been treated for colorectal cancer in our 
hospital since 1984 were derived from the cancer registry of the Comprehensive 
Cancer Centre South. From this database two groups were selected for further 
study. The first group comprised all patients who met the following criteria: (1) 
Bolus chemotherapy with 5-FU and LV had been initiated between January 1994 
and December 1997 because of irresectable metastatic disease and no previous 
therapy had been given for these metastases. (2) The performance status- as 
estimated by the treating physician- had to be 0 or 1. The second group 
comprised all patients who met the following criteria: (1) Irresectable metastatic 
disease was diagnosed between January 1984 and december 1989. In this period 
chemotherapy was never applied for patients with advanced colorectal cancer. (2) 
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Patients were younger than 76 years old and their performance status- as 
estimated by their treating physician was 0 or 1. (3) No previous treatment had 
been given for the metastases. 
Both groups were entered in an analysis on the relation between chemotherapy 
and survival. Survival was measured from the time of diagnosis of the 
metastases. The medical records of all selected patients were also screened for 
the following -potentially confounding- variables: Age at the time of metastasis; 
Lactate dehydrogenase concentration at the time of metastasis (<= 300 units/litre 
vs 301- 450 units/litre vs > 450 units/litre); Hemoglobin concentration at the time 
of metastasis (<= 7.8 mmol/litre vs 7.9- 8.5 mmol/litre vs > 8.5 mmol/litre); 
Carcinoembryonic Antigen concentration at the time of metastasis (<= 10 
microgram/litre vs 11- 50 microgram/litre vs >50 microgram/litre; Location of 
metastases; Surgical intervention for the primary tumor (palliative versus 
resection). The significance of a relation between one of the mentioned 
parameters and survival was calculated by means of the logrank test. Variables 
which showed a significant relation with survival (P-value < 0.05) were entered in 
a proportional hazards regression analysis. 
Results 
Thirty nine treated patients and 79 untreated controls were selected for analysis. 
Seventy one patients were male and 47 female. Their median age was 64 years. 
The 39 treated patients had received chemotherapy for a median period of 7 Va 
months. In all patients chemotherapy was initiated at the time of diagnosis of the 
metastases. Fourteen patients (36%) had progressive disease and 18 patients 
(46%) had stable disease. Five partial responses (13%) and one complete 
response (3%) were achieved. In one patient the response was unknown. 
In the univariate analysis two variables showed a significant relation with survival: 
chemotherapy and location of metastases. Figure 1 shows the relation between 
chemotherapy and survival. The median survival was 11 months for the treated 
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Figure 1. Survival of patients with advanced colorectal cancer: patients who were treated with bolus-
injections of 5-fluorouracil and leucovorin versus patients who received supportive care only. Survival 
was significantly better for the former group ( logrank test, p= 0.009 
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Table 1 shows the median survival according to the location of the metastases 
Patients with metastatic disease confined to liver and/or lungs had the best 
prognosis (p= 0 006) Chemotherapy and location of metastases both retained 
their significance (P-values 0 036 and 0 025, respectively) in a proportional 
hazards regression analysis 
Location of metastases 
Liver and/or lungs 



















Table 1 Median survival of patients with advanced colorectal cancer according to location of 
metastases 
Discussion 
In the last two decades the treatment of patients with ACC has changed 
considerably In case of a limited number of pulmonary or hepatic metastases 
resection is a fully accepted treatment option which may even lead to cure4 8 For 
patients with more advanced disease the use of chemotherapy was gradually 
introduced as a treatment option and nowadays there is general acceptance 
among medical oncologists 
Studies adressmg the question whether first-line chemotherapy prolongs life in 
comparison to best supportive care are rare Table 2 shows the studies published 
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so far. In the 2 largest studies patients were randomized to either primary 
expectancy or chemotherapy. In case of symptoms patients who were initially 

































































Table 2. Overview of the studies in which the impact of 5-FU-based bolus chemotherapy on survival 
was evaluated in patients with advanced colorectal cancer ( 5-FU= 5-fluorouracil, LV= leucovorin, 
MTX= methotrexate). 
In the study by the Nordic Gastrointestinal Tumor Adjuvant Chemotherapy Group 
this took place in 57% of patients and in the study by Scheithauer et al. in 17% of 
patients1,2. Therefore, the analyses could not show the true impact of 
chemotherapy. In fact, only one study, which comprised only 36 patients, has 
shown a significant survival advantage for patients who received chemotherapy2. 
Therefore, we think that our study adds useful information. It compared two 
groups of patients: untreated patients selected from a period in which 
chemotherapy was never given and treated patients selected from a period in 
which this treatment was recommended to all motivated patients. Therefore, the 
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chance of treatment selection was small. Both groups were comparable in terms 
of age and performance status. There is no reason to believe that either group 
received better supportive care. In our study group chemotherapy appeared to be 
an independent positive prognostic factor for survival, although the gain in median 
survival was rather small. The treatment was usually well tolerated and a previous 
evaluation did not show a serious infliction on the quality of life9. The treatment 
regimen described is applied by many clinicians and its toxicity is low. A meta-
analysis of 9 slightly differing studies has shown survival figures comparable to 
ours10. For treatment outside clinical trials this regimen appears a useful option. 
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Abstract 
Background: Currently there is no standard second line treatment for patients with 
advanced colorectal cancer ( ACC). Previous reports have demonstrated that 
some patients may benefit from second line infusional 5-fluorouracil ( 5-FU) after 
failing 5-FU bolus treatment. 
Patients and methods: We retrospectively studied the efficacy and toxicity of 
infusional 5-FU regimens given in second line, which only differed from the first 
line regimen in the type of biochemical modulation and compared these results in 
a non-randomized fashion to the outcome of patients receiving supportive care 
only in second line. 
Results: Sixty six patients with ACC were treated in first line with an infusional 5-
FU-based schedule. At the time of disease progression 38 patients received 
supportive care only. The remaining 28 patients continued treatment with the 
same 5-FU regimen, but with another biochemical modulator. Fourteen patients 
achieved stable disease for a median duration of 6 months and one patient 
achieved a complete remission which lasted 34 months. The median survival from 
the time of disease progression on first line treatment was 7 months for patients 
who received second line treatment, whereas those who received supportive care 
only survived for a median period of 3 months ( p< 0.05). 
Conclusion: Changing the type of biochemical modulation of infusional 5-FU as a 
second line treatment-alternative may be of some benefit to a subgroup of 
patients with ACC. 
Introduction 
5-fluorouracil ( 5-FU) is the most widely used agent in the treatment of advanced 
colorectal carcinoma ( ACC). During the last decades research has focussed on 
the optimal administration schedule of 5-FU and on agents which biochemically 
modulate the cytotoxic effect of 5-FU. 5-FU may be administered either as a bolus 
or as a continuous infusion. While higher response rates have been reported for 
continuous infusion schedules, this has not yet resulted in a survival benefit1,2. 
Agents that effectively modulate 5-FU activity are leucovorin ( LV) and 
98 
methotrexate ( MTX)3,4. Other modulators that have been tested in clinical trials 
include interferon-α ( IFN-a) and N-phosphonacetyl-L-aspartic acid ( PALA)5,6. For 
patients resistant to first line treatment with 5-FU no standard treatment is 
available.Several small studies have been published on the use of infusional 5-FU 
in patients resistant to 5-FU bolus therapy7"10. No data exist on the efficacy of 
second line treatment with infusional 5-FU in combination with a different 
biochemical modulator and only very few studies have been reported on second 
line bolus 5-FU in combination with a different biochemical modulator. The 
rationale behind these options is that the mechanisms of underlying 5-FU 
resistance might differ depending on the kind of 5-FU schedule or the type of 
biochemical modulator used. We studied the efficacy and toxicity of infusional 5-
FU regimens given in second line, which only differed from the first line regimen in 
the type of biochemical modulation. 
Patients and methods 
From 1988 until 1993 66 patients with ACC were entered in 3 different 
studies11"13. In all patients an infusional 5-FU regimen of 60 mg/kg/48 hours was 
used. The treatment schedules used in these studies are shown in table 1. 
Response was evaluated with an interval of 2 to 3 months. Complete response ( 
CR), partial response ( PR), stable disease ( SD) and progressive disease ( PD) 
were defined according to WHO criteria. Of these 66 patients 28 patients with PD 
continued treatment with the same schedule of 5-FU, but with a different 
biochemical modulator than the one used in first line treatment. Patients initially 
treated with 5-FU alone received 5-FU plus LV and patients initially treated with 5-
FU plus LV and IFN-a received 5-FU and MTX. Furthermore, patients treated with 
5-FU, PALA and MTX received 5-FU and LV and patients treated with 5-FU and 
MTX received 5-FU and LV.The major selection criteria for second line therapy 
were performance status, motivation of the patient for further therapy, as well as 






































over 4Θ hours 
Continuous iv 
over 4Θ hours 
Bolus iv. 
Continuous iv. 















Every 6 hours 8 
doses 
Day 1,3 and 5 
Table 1. Schedules according to which the 66 patients studied had been treated. Treatment was given 
every week during the first month and every 2 weeks thereafter ( iv= intravenous; s.c.= subcutaneous; 
the regimen numbers correspond with the references). 
Patients who did and patients who did not receive second line chemotherapy 
were compared in terms of overall survival, response rate to first line 
chemotherapy and progression-free survival, as well as performance status at the 
time of discontinuation of first line chemotherapy. The significance of differences 
between stochastic variables was estimated by means of the Chi-square test. The 
significance of differences between actuarial survival curves was estimated by 
means of the Anderson log rank-test. 
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Results 
For the entire group of 66 patients first line chemotherapy resulted in 34 SD's 
( 52%) and 8 PR's ( 12%). CFTs did not occur. In 24 cases ( 36%) the disease 
appeared progressive. The median progression-free interval was 6 months. 
After disease progression twenty eight patients continued chemotherapy with the 
same 5-FU schedule, but with a different biochemical modulator. Table 2 shows 
the responses and survival of these patients. Fourteen patients ( 50%) achieved 
SD for a median duration of 6 months and one patient ( 4%) achieved a CR which 
lasted 34 months. The median progression-free interval was 4 months. Median 
survival measured from the moment of disease progression during first line 
treatment was significantly better for the 28 patients who had received second 
line chemotherapy than for the 38 patients who had received supportive care only 
( 7 months versus 3 months, ρ < 0.05). 
Grade 1 -2 toxicities occurred in 17 patients on second line chemotherapy ( 61 %) 









































































































































































































































































































































Table 2 An overview of all patients who received first and second line treatment for advanced 
colorectal cancer ( CR, PR, SD and PD denote complete response, partial response, stable disease 
and progressive disease, respectively, M= male, F= female) 
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As shown in tables 3 and 4, the patients who received second line chemotherapy 
differed considerably from the patients who received supportive care only. Among 
the former the proportion of patients with SD or PR to first line chemotherapy was 
higher ( ρ < 0.05) and the median progression-free interval from the start of first 
line chemotherapy was longer ( 8 months vs 3 months, p< 0.01). The median 
Karnofsky performance status was better at the time of discontinuation of first line 
chemotherapy ( 90% vs 70%). Furthermore, their median overall survival from the 













Patients who received 
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Patients who did not receive 
second line chemotherapy 





Table 3. Actuarial survival of 66 patients with advanced colorectal cancer who received first line 
chemotherapy The survival is also depicted for the patients who did and the patients who did not 
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Percentage of patients free from 
progression after first line 
chemotherapy 
6 months follow up 
12 months follow up 
18 months follow up 
Median Karnofsky performance 
status at the time of 




( n= 28) 
23 ( 82%) 
5(18%) 
22 ( 79%) 
1(3%) 
3(11%) 
2 ( 7%) 
6(21%) 





No second line 
chemotherapy 
( n= 38) 
28 ( 74%) 
10(26%) 
25 ( 66%) 
8(21%) 
2 ( 5%) 
3 ( 8%) 
18(47%) 





Table 4 Characteristics of the patients who did and the patients who did not receive second line 
chemotherapy ( PD= progressive disease, SD= stable disease, PR= partial remission) 
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Discussion 
At present, most patients with ACC are treated in first line with a 5-FU-based 
regimen. In case of progression, there is no standard second line regimen 
available. Several studies indicate that in some patients with disease progression 
on first line treatment with bolus 5-FU a response or stabilization of disease can 
be induced by administration of an infusional schedule with high-dose 5-FU7"10. In 
these studies response rates ( CR and PR) varied from 5 to 30% with a median 
overall survival of 7.5 to 10 months. 
Our study adresses the question whether patients with ACC refractory to 
treatment with a combination of infusional 5-FU and one or more biochemical 
modulators may benefit from a second line regimen consisting of the same 5-FU 
schedule, but with a different modulator. Publications concerning this question are 
scarce. Bernhard et al. studied the value of the addition of IFN-I in 15 patients 
refractory to treatment with 5-FU and LV14. Only one minor response and one SD 
were observed. In a study performed by Palmieri et al. 20 patients with ACC 
refractory to treatment with 5-FU or 5-FU plus LV received a second line schedule 
consisting of 5-FU and MTX15. Two PR's were observed and 12 patients 
achieved SD. The second line schedules in our study ( infusional 5-FU plus MTX 
or LV) resulted in 14 SD's and 1 CR in 28 patients. 
In our study, the baseline characteristics of the patients who received second line 
chemotherapy clearly differed from those of patients who had received supportive 
care only. A larger proportion had benefitted from first line chemotherapy in terms 
of response and response duration. Furthermore, they were in better condition at 
the time of disease progression on first line treatment. Second line treatment was 
not initiated in a prospective randomized fashion and the patients who received 
second line treatment represent a selected group. Differences in survival between 
treated and untreated patients are therefore not informative. However, our results 
suggest that selected patients refractory to infusional 5-FU may have some 
benefit from second line treatment with 5-FU in combination with a different 
biochemical modulator. Alternative possibilities for the treatment of 5-FU resistant 
ACC are irinotecan ( CPT-11) and 5-FU-modulation by trimetrexate, since these 
agents have shown promising results in phase ll-studies16,17. 
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Purpose: Local hypoxia has been linked to a higher risk of metastasis in 
patients with cancer of the uterine cervix and a hemoglobin concentration of 7.45 
mmol/L or less. It is unknown whether the same holds true for rectal cancer. We 
evaluated the independent impact of preoperative anemia on survival in patients 
with rectal cancer. 
Patients and methods: A random set of 144 patients diagnosed with Dukes 
A, Β or C rectal cancer in the period 1995-1999 and registered in the database of 
the Eindhoven Cancer Registry was included in a survival analysis. Parameters 
tested were gender, age, preoperative hemoglobin concentration, tumor stage 
and therapy. The ones that showed a relation with survival ( Log Rank test, ρ < 
0.1) were entered in a multivariate analysis. 
Results: For patients without preoperative anemia the hazard ratio of death was 
0.35 ( 95%-confidence interval 0.19- 0.65, p= 0.001), which indicates a three 
times lower mortality risk. For patients with a higher tumor stage (Dukes Β versus 
Dukes A or Dukes C versus Dukes B) the hazard ratio of death was 1.52 ( 95%-
confidence interval 1.04- 2.23, p= 0.03). For older patients ( 64- 73 years versus < 
64 years or >73 years versus 64- 73 years) the hazard ratio of death was 1.85 ( 
95%-confidence interval 1.29- 2.63, p= 0.001). 
Conclusion: Longterm survival was significantly affected in rectal cancer 
patients with preoperative anemia. Further study on the relation between anemia, 
tumor oxygenation and prognosis is needed, as it may have implications for future 
therapy. 
Introduction 
In patients with rectal cancer current research focusses on finding the most 
perfect combination of surgery, adjuvant radiotherapy and adjuvant 
chemotherapy. In this context tumour hypoxia is a very interesting phenomenon 
and much can be learned from a neighbour organ, the uterine cervix. Studies on 
cancer of the uterine cervix have revealed that tumour hypoxia is promoted by 
anemia and poor tumor vascularization1"8. Vaupel et al. have recently shown a 
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clear deterioration in tumour oxygenation status in patients with a hemoglobin 
concentration below 12 g/dl ( < 7.45 mmol/L)9. Tumour hypoxia can worsen 
prognosis in three ways. It promotes neovascularization, which appears to 
facilitate local tumor spread and distant metastasis1"8. Furthermore, it has been 
linked to radiotherapy resistance and there is a rich literature on 
chemotherapeutic agents which depend on tumour oxygenation status for their 
therapeutic efficacy10. 
Wendung et al. have previously reported that hypoxia occurs in rectal 
adenocarcinomas and that tumour stage and oxygenation status are not related11. 
From this finding one could hypothesize that preoperative anemia is of 
independent prognostic significance in patients with rectal cancer. A study by 
Zorzitto et al. is the only one which confirms this hypothesis. In their retrospective 
analysis, the mortality risk was twice as high in patients with preoperative 
anemia12. In the present study we evaluated whether their results were 
reproducible. 
Materials and methods 
Dafa collection 
The Eindhoven Cancer Registry covers a large part of the southern Netherlands 
with approximately two million inhabitants. This registry is notified by six 
pathology departments, hospital medical records offices in 17 community 
hospitals (no university hospitals) and two radiation therapy institutes. From the 
population-based database of the Eindhoven Cancer Registry we obtained a 
random set of 144 patients who had been operated on in the period 1995-1999 
because of Dukes A, Β or C rectal cancer13,14. 
From their patient records we derived data on: gender ( male versus female), age 
at the time of diagnosis ( < 63 years, 64- 73 years, > 73 years), hemoglobin 
concentration at the time of diagnosis ( 7.4 mmol/L or less versus more than 7.4 
mmol/L), tumour stage ( Dukes A, Β and C), adjuvant chemotherapy ( yes versus 
no) and adjuvant radiotherapy ( yes versus no). Vital status of all patients on the 
1 st of august 2003 was assessed through the Central Bureau of Genealogy, an 
institution in which all deceased persons in The Netherlands are registered. 
i l l 
>4na/ys/s 
The sole endpoint of this study was overall survival. Kaplan Meier curves were 
calculated for all the parameters mentioned above. The significance of differences 
in survival was estimated by means of the Log Rank test. All parameters which 
showed a significant or borderline significant ( p-value 0.1 or less) relation with 
survival in the univariate analysis were included in a conditional logistic 
regression analysis in order to discriminate the ones with independent prognostic 
significance. In the conditional logistic regression analysis p-values of 0.05 or less 
were considered significant. For all statistical calculations the SPSS 11.0 for 
windows-software was used. 
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Results 
The study group comprised 144 patients and 59 of them had died in the follow up 
period. Eighty five patients were male and 59 female. The preoperative 
hemoglobin concentration had been measured in 125 patients and the distribution 
of the measurement results is shown in figure 1. 
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Figure 1. Distribution of preoperative hemoglobin concentrations as measured in 125 patients with 
Dukes A- C rectal cancer who had been registered in the period 1995-1999 in the database of the 
Comprehensive Cancer Centre South, the Netherlands. 
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Table 1 shows survival according to the different parameters examined. The 
median survival of patients with a preoperative hemoglobin concentration higher 
than 7.4 mmol/L was twice as long as the survival of patients with a lower 
concentration ( figure 2). 
Parameter tested 
Hemoglobin concentration 
7 4 mmol/L or less 







63 years or younger 
64- 73 years 






Surgery and radiotherapy 



















Median survival in 
months (95%CI) 
39 ( 24- 54) 
77 ( 69- 84) 
n.a 
81 (71-92) 
63 ( 53- 73) 
61 ( 49- 73) 
79(71-86) 
69(57-81) 
50 ( 38- 62) 
72 ( 65- 80) 
62(51-73) 
76 ( 69- 84) 
55 ( 44- 67) 
46 ( 33- 59) 
60(31-88) 







Table 1 Median survival according to several parameters in a random set of 144 patients with Dukes 
A- C rectal cancer who had been registered in the period 1995-1999 in the database of the 
Comprehensive Cancer Centre South, the Netherlands ( η a = not applicable) 
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Figure 2 Survival according to preoperative hemoglobin concentration in 125 patients with Dukes A- C 
rectal cancer who had been registered in the period 1995-1999 in the database of the Comprehensive 
Cancer Centre South, the Netherlands. The dotted line represents patients with a concentration of at 
least 7 5 mmol/L. The continuous line represents patients with a hemoglobin concentration of 7 4 
mmol/L or less. Tick marks represent censored patients. 
Preoperative hemoglobin concentration, tumour stage, gender and age were 
eligible for the conditional logistic regression analysis. In this analysis ( 125 
complete data sets) gender lost its significance ( p= 0.976). As table 2 shows, 
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Table 2. A random set of 144 patients with Dukes A- C rectal cancer who had been registered in the 
period 1995-1999 in the database of the Comprehensive Cancer Centre South, the Netherlands; 
Factors which showed a relation with survival in the univariate analysis stratified according to 
preoperative hemoglobin concentration. 
Nevertheless, for patients without preoperative anemia the hazard ratio of death 
was 0.35 ( 95%-confidence interval 0.19- 0.65, p= 0.001), which indicates a three 
times higher mortality risk for anemic patients. For patients with a higher tumour 
stage (Dukes Β versus Dukes A or Dukes C versus Dukes B) the hazard ratio of 
death was 1.52 ( 95%-confidence interval 1.04- 2.23, p= 0.03). For older patients 
( 64- 73 years versus < 64 years or >73 years versus 64- 73 years) the hazard 
ratio of death was 1.85 ( 95%-confidence interval 1.29- 2.63, p= 0.001). 
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Discussion 
The primary goal of our analysis was to evaluate whether preoperative anemia 
was related with a poorer overall survival in patients with Dukes A- C rectal 
cancer. The patients included in the analysis had been taken at random from a 
larger population-based database and rectal cancer surgery had taken place in 
different hospitals. In the study period all these hospitals participated in the TME-
trial, which means that total mesorectal excision was considered the standard 
surgical procedure15. There were some weaknesses in the study design: 
Firstly, in 19 out of 144 patients the preoperative hemoglobin concentration had 
not been registered, which could have biased the results. Table 2 however 
suggests that there were no serious imbalances between patients with known and 
patients with unknown preoperative hemoglobin concentrations. 
Secondly, due to the limited number of patients included, the hemoglobin 
concentration could not be entered in the analysis as a continuous variable. The 
cut-off value of 7.4 mmol/L was based on a study by Vaupel et al. in patients with 
cancer of the uterine cervix. A hemoglobin concentration below 7.45 mmol/L was 
related with a strong deterioration in tumor oxygen tension9. There are no 
comparable studies which have been performed in patients with rectal cancer. 
There is however no reason to believe that the relation between hemoglobin 
concentration and tumor oxygen tension would not exist in rectal cancer. 
Thirdly, it is unknown whether the patients in our analysis died due to non-
malignant disease, local tumor recurrence or distant metastasis. We however do 
not think that the results could have been biased by an imbalance in deaths due 
to non-malignant disease. For all patients, data on comorbidity were available13. 
Patients with a hemoglobin concentration of 7.4 mmol/L or less and patients with 
a higher hemoglobin concentration did not significantly differ in terms of 
comorbidity ( data not shown). 
Our study is the second one, which underlines a possible relation between 
preoperative anemia and survival in patients with rectal cancer12. In spite of the 
weaknesses mentioned earlier, the results of our analysis justify further study. 
The study concept ( to unravel the relation between anemia and tumor behaviour 
in cancer and to develop treatment methods based on these findings) has already 
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proven to be successful in the treatment of head and neck cancer and cervical 
J 6-22 
cancer 
Future research should focus on two aspects of anemia: 
The independent prognostic value of preoperative anemia should be tested in 
randomized prospective trials on rectal cancer treatment. If preoperative anemia 
should turn out to be related with a higher chance of cancer recurrence, it should 
play a role in the decision whether or not to apply adjuvant therapy. 
Furthermore, small-scale in-vivo studies should be performed to test the relation 
between hemoglobin concentration and tumor oxygenation in rectal cancer 
patients. New magnetic resonance imaging techniques offer the opportunity of 
non-invasive oxygen tension measurement. An increase in tumor oxygenation, 
achieved for instance by means of anemia correction, might improve the efficacy 
of preoperative radiotherapy. 
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Abstract 
Cancer cachexia, defined as involuntary weight loss and tissue wasting due to 
cancer, negatively influences physical condition, quality of life and prognosis. 
Wellknown causes, such as ileus or hypercalcemia, do not suffice to explain the 
entire phenomenon. Metabolic changes induced by tumor and/or host are 
supposed to play a deciding role. In the present review current insights in etiology 
and treatment are discussed. 
Introduction 
Cancer cachexia - which is defined as involuntary weight loss and tissue wasting 
due to cancer - negatively influences physical condition and cancer treatability, 
quality of life and prognosis1,2. At least 50% of all cancer patients will experience 
weight loss somewhere in the course of their disease and this problem usually 
becomes more pronounced when the disease progresses3. In more than 20% of 
patients cachexia is the main cause of death4 . Therefore, this disorder deserves 
therapeutical attention, especially if cancer treatment is to be given. Research has 
provided much insight in the etiology of cancer cachexia and new treatment 
options are being tested. In this article, we summarize the etiological aspects, 
which can be divided in decreased intake and increased catabolism. The various 
treatment options which should be considered in daily practice are discussed. 
Etiological aspects 
(1): - Decreased intake 
A decreased intake can be due to treatment-related toxicities, such as nausea 
due to chemotherapy, radiotherapy or opiates, or to the disease itself. Examples 
of the latter are pain, gastrointestinal obstruction, depression, malabsorption and 
hypercalcemia. 
(2):- Increased catabolism due to the production of certain 
substances 
The metabolic processes of cancer cachexia and starvation differ considerably. 
For instance, the concentration of melanocortin, a regulatory protein which 
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induces anorexia and alters taste, decreases in case of starvation, but not in case 
of cancer cachexia5"7. Whereas starving patients are very hungry at the 
beginning, patients with cancer cachexia lack appetite8. Moreover, muscle tissue 
loss is much more prominent in case of cancer cachexia than in case of 
starvation9,10. These phenomena may be induced by substances produced by 
tumor and/or host. In this context, cytokines, such as Tumor Necrosis Factor-
alpha ( TNF-a) - also known as cachectin- and lnterleukin-6 ( IL-6), have 
received much attention. Animal experiments suggest that these cytokines 
facilitate anorexia, lipolysis, proteolysis and gluconeogenesis11"17. For this reason 
it is tempting to test the cachexia-inhibiting effect of cytokine-antibodies. Up to 
now, the hypothesis that the process of cancer cachexia can be attenuated by the 
administration of cytokine-antibodies is supported by only one small patient 
study18. The lack of a significant correlation between IL-6 or TNF-a concentration 
and degree of weight loss suggests that these cytokines do not play a central role 
in the cancer cachexia process19"27. 
Two other substances have drawn a lot of attention during the last two decades: 
lipid-mobilizing factor and proteolysis-inducing factor. In the eighties, a lipolysis-
inducing substance was isolated from extracts of the MAC16 tumor. This 
substance, which was present in serum of patients with cancer cachexia, but not 
in serum of normal or starving patients, was called the MAC16 lipid factor28'30. In 
later studies, this factor was called lipid mobilizing factor31"33. In a murine 
experiment with a non-cachexia-inducing tumor the administration of lipid 
mobilizing factor led to significant weight loss30. By using the same murine 
experimental model Todorov et al. have more recently identified a 24KD 
proteoglycan which induces skeletal muscle proteolysis ( proteolysis-inducing 
factor or PIF)34. The catabolic action of PIF could be neutralized by the 
administration of monoclonal antibodies34 . Moreover, PIF appeared present in 
the urine of weight-losing cancer patients, but not in the urine of patients with no 
or little weight loss34. Cabal-Manzano et al. found a significant correlation 
between urinary PIF-concentration and degree of weight loss in patients with 
gastrointestinal tumors35. 
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(3): Increased catabolism due to accelerated hepatic 
gluconeogenesis 
In the past 35 years many studies have revealed the parasitic nature of a tumor. It 
requires a substantial amount of energy for its continuous growth. The amount of 
energy released by catabolism of glucose, fatty acids, or amino acids is maximal 
in the presence of abundant molecular oxygen ( aerobic catabolism), but minimal 
in its absence. Anaerobic catabolism of glucose generates only 5 % of the energy 
yielded by aerobic catabolism of glucose. The final product is lactate, rather than 
the carbon dioxide and water that are produced under aerobic conditions. Holm et 
al. have previously found up to 43-fold increased lactate concentrations in the 
draining vein of a human colorectal carcinoma in comparison with the femoral 
vein, which proves that the anaerobic catabolism of glucose is an important 
energy source36. If the oxygen supply to the tumor remains constant in the 
presence of an ever-increasing tumor mass, oxygen becomes the limiting factor 
of energy generation inside the growing tumor. Under aerobic conditions a 
mammalian cell will metabolize equicaloric amounts of glucose and fatty acids. 
Under anaerobic conditions it completely depends on glucose fermentation, 
because it cannot ferment fatty acids. Hence, tumor cells will need to consume at 
least 40 times more glucose to generate an equal amount of energy as under 
aerobic conditions from normal dietary glucose and fatty acids just to survive. 
Thus, a tumor with hypoxic areas requires more glucose for the maintainance of 
its growth. Once the alimentary intake is insufficient to provide the required 
amount of glucose, additional glucose is synthesized by hepatic gluconeogenesis. 
Whereas the anaerobic generation of 2 moles of lactate from 1 mole of glucose 
yields 2 moles of ATP ( anaerobic glycolysis), the regeneration of 1 mole of 
glucose from 2 moles of lactate ( gluconeogenesis) requires 6 moles of ATP. This 
cyclic process of anaerobic glycolysis and gluconeogenesis, which is called the 
Cori cycle, has been shown to be significantly more active in cachectic patients 
than in non-cachectic controls37"39. The additional energy (6 ATP per mole 
glucose) which is required to keep the Cori cycle functioning is produced in the 
liver by aerobic catabolism of fatty acids and amino acids. Due to the continuous 
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character of this process body fat and muscle proteins are lost, which leads to 
weight loss.This increased hepatic gluconeogenesis due to the anaerobic 
catabolism of glucose in the tumor is probably the most important cause of cancer 
cachexia40. 
Treatment options 
(1): - Treatment targeted at increase of intake 
If intake remains insufficient in spite of adequate alleviation of causes, such as 
treatment- related nausea or ileus, artificial feeding could be applied. Tube 
feeding or intravenous feeding has however not been shown to improve lean 
body mass or overall prognosis41"47. Moreover, such feeding obviates the 
satisfaction of tasting and swallowing food. It is therefore not generally advocated 
in a palliative setting. However, it can be of great value in patients with upper 
gastointestinal tract obstruction due to tumor. 
(2): - Treatment targeted at inhibition of cachectic factors 
(a) Glucocorticoids: 
Glucocorticoids have been shown to have a short-lasting beneficial effect on 
appetetite, food intake, sensation of well-being and performance status. There is 
however no positive effect on lean body mass48"50. It is generally recommended to 
administer a daily dose of 30 mg of prednison or an equivalent dose of another 
glucocorticoid at a one week-trial basis. The medication should be given in the 
morning or early afternoon to avoid overnight insomnia. In the second week 
treatment should only be continued in case of a beneficial effect. Such a 
beneficial effect usually lasts a few weeks, whereas side effects can become 
disturbing. 
(b) Progestagens: 
In several randomized prospective clinical trials administration of high-dose 
medroxy progesterone acetate or megestrol acetate resulted in increased lean 
body mass and improved appetite 48'49'51"59. This beneficial effect is supposed to 
be due to down regulation of cachectic cytokines, such as IL-660. The 
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recommended dose for medroxyprogesterone acetate is 600 mg daily. Megestrol 
acetate has been shown to be more effective at higher doses; if possible, the 
starting dose of 160 mg per day should be escalated up to 800 mg per day55. 
Such treatment is usually well tolerated, but there is an increased risk of 
thromboembolic complications.The therapeutic efficacy has been estimated in a 
recent meta-analysis. In case of treatment with a high-dose progestagen the odds 
of gaining weight was 2.66 ( 95%-confidence interval 1.80- 3.92) and the odds of 
an improved appetite was 4.23 ( 95%-confidence interval 2.53-7.04)61. 
( c) Polyunsaturated fatty acids: 
Eicosapentanoic acid (EPA), a polyunsaturated fatty acid, has been widely 
studied in animals and has demonstrated inhibition of lipolysis and muscle protein 
degradation associated with a cachexia model33,48,52. In a clinical study among 26 
patients with pancreatic cancer an EPA-dose of 6 grams per day resulted in a 
median weight gain of 0.5 kg and other small-scale studies have revealed 
comparable results 62"65. The only randomized controlled trial however failed to 
show a nutritional benefit in comparison with placebo, but performance status and 
survival appeared to improve66. Large-scale prospective studies are needed to 
estimate the therapeutic potential of EPA, but firstly the dose -response 
relationship should be outlined. Sensation of fullness, nausea, bowel cramps and 
steatorrhoe appear to be the dose-limiting toxicities67. 
(d) Others 
Substances, such as thalidomide, melatonine and nonsteroidal anti-inflammatory 
drugs, appear to alleviate differing aspects of cancer cachexia, but there is until 
now no sufficient basis for daily practice application68"72. 
(3): Treatment targeted at attenuation of hepatic 
gluconeogenesis 
Interventions aimed at improvement of tumor oxygenation may decrease the rate 
of glucose fermentation and subsequently attenuate the rate of hepatic 
gluconeogenesis. This attenuation will result in less weight loss. In this context 
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erythropoietin is a very interesting substance. It is more and more applied to 
cancer patients, because it decreases the need for blood transfusions and 
improves quality of life73"76. It is questionnable whether the improvement in quality 
of life is a mere result of increased hemoglobin concentration. In a murine cancer 
cachexia model, treatment with recombinant human erythropoietin resulted in 
attenuation of weight loss77. This may be due to an improvement in tumor 
oxygenation mediated by the rise in hemoglobin concentration. In 2 small studies, 
cancer patients treated with recombinant human erythropoietin ( 12000- 30000 
units of Epoetin Alfa per week) indeed lost less weight than untreated 
controls78,79. Erythropoietin-mediated attenuation of weight loss may play an 
important role in the improvement of quality of life. Therefore, in future 
randomised prospective trials on erythropoietin and quality of life changes in body 
weight should be recorded. 
Conclusions 
Cachexia is a very serious complication in cancer patients. Its etiology is 
multifactorial and its treatment should always be individualized. Firstly, each 
patient should be screened for the common treatable causes and treatment 
should be applied accordingly. If the cancer cachexia syndrome still prevails, the 
patient could be entered in a clinical trial on polyunsaturated fatty acids or 
progestagens. Outside clinical trials, medroxyprogesterone or megestrol acetate 
could be prescribed to patients without a history of serious thrombo-embolic 
complications. A treatment attempt could also be made with a glucocorticoid. 
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A review-based hypothesis is presented that covers the pathogenesis of cancer 
cachexia and that centers on the hypoxic condition of tumors, the essential 
metabolic consequences, and the adaptation of the body. 
In growing tumors the 0 2 concentration is critically low. Mammalian cells 
need O2 for the efficient oxidative dissimilation of sugars and fatty acids, which 
gives 38 and 128 moles of ATP per mole glucose and palmitic acid, respectively. 
In the absence of sufficient O2 they have to switch to anaerobic dissimilation, with 
only 2 moles of ATP and 2 moles of lactic acid from 1 mole of glucose. Since 
mammalian cells cannot ferment fatty acids, tumor cells completely depend on 
glucose fermentation. Growth of tumor cells will therefore require about 40 times 
more glucose. 
Since lactic acid lowers the intracellular pH, it decreases the activity of 
pyruvate dehydrogenase, stimulates fermentation, and thus amplifies its own 
fermentative production. Compensatory glucose is provided by hepatic 
gluconeogenesis from lactic acid. However, the liver must invest 3 times more 
energy to synthesize glucose than can be extracted by tumor cells in an 
anaerobic way. The liver extracts the required energy from amino acids and 
especially from fatty acids in an oxidative way. This may account for the weight 
loss, even when food intake seems adequate. 
In the liver the energy content of 4 out of every 6 moles of ATP, which are 
invested in the gluconeogenesis of one mole of glucose, is dissipated as heat. 
This may account for the elevated body temperature and sweating experience by 
cancer patients. 
Introduction 
Many chronic or end-stage diseases, such as cancer, infectious diseases, AIDS, 
congestive heart failure, rheumatoid arthritis, tuberculosis, cystic fibrosis and 
Crohn's disease, are associated with cachexia, and it can also develop in elderly 
people who do not have any obvious disease symptoms (1,2). Although cachexia 
represents the complex metabolic state that is seen in such patients, it is 
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commonly recognized as progressive weight loss with depletion of host reserves 
of adipose tissue and skeletal muscle (1). 
Many investigators have tried to explain the relation between cachexia and 
cancer (1). The isolation of a mainly lactate consuming bacterium from the 
thoracic vertebra of a patient with spinal osteomyelitis, considerable weight loss 
and possibly metastasis (unpublished results), prompted us to try to explain not 
only the massive emergence and the fate of lactic acid, but also the relationship 
between cachexia and cancer in terms of human metabolism. We therefore 
created a hypothesis that contains some important elements that have been 
hypothesized also in 1968 by Gold (3) and in 1992 by Dills (4). Our approach is 
mainly based on the production and usage (i.e., flow) of energy (as expressed in 
ATP-units). This is essentially different from the approaches of either Gold or 
Dills, which are mainly based on the coherence of dissimilatory biochemical 
processes as such in cachectic animals or humans with tumors (3,4). 
We postulate that cancer cachexia can be fully explained by the energetic 
consequences of the growing tumor, which changes from aerobic to anaerobic 
dissimilation locally and causes metabolic adaptation in the liver. In the patients 
with cancer the tumor cells are no longer subjected to the growth control of the 
body (5,6). When tumor growth is beyond a certain size, body weight decreases 
(7). The substantial weight loss which is often observed, and which is known as 
cancer cachexia, can generally not be explained by a decreased dietary intake 
alone (8). Cachectic patients appear to be in a catabolic condition. It has been 
known for 70 years that tumors demonstrate changed metabolic profiles with 
hypoxia in the growing tumor (9,10) and increases in glucose uptake (11), 
glycolysis and lactate production. A human colorectal carcinoma has been 
reported to produce up to 43-times the normal lactate concentration in the 
draining vein (12). It is known that in the patients with cancer cachexia the Cori-
cycle has increased activity (13-15). This cycle consists of the fermentation of 
glucose to lactic acid in the tissues, and the conversion of lactic acid to glucose in 
the liver (16). To date, little attention has been paid to the energetic implications 
of this metabolic pathway, but in our view this may completely elucidate the cause 
of cancer cachexia. 
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Tumor growth 
Normally, the growth rate of all body cells is continuously under control. The most 
important feature of a tumor cell is that to a great extent these cells withdraw from 
normal growth regulation. Tumor cell growth is determined by the rate of 
biosynthesis of essential cellular components (as various structural components, 
enzymes, chromosomes and membranes). Critical factors, that affect the growth 
rate of tumor cells are; (i) the rate of energy generation and the subsequent 
uptake rate of both energy-rich substrates and oxygen (ii) the uptake rate of 
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Figure 1 Schematic representation of energy yields in aerobic conditions from both glucose and 
palmitic acid The first dissimilatory steps are different, but the complex dissimilatory processes from 
acetyl-CoA to CO2 and H2O (in TCAC) are exactly the same Concerning glucose the first steps 
involve the 2-fold glycolytic production of pyruvic acid and the PDH-mediated decarboxylative 
conversion of pyruvic acid to acetyl-CoA Concerning palmitic acid the first steps involve the 8-fold 
production of acetyl-CoA from the C(16)-fatty acid via C(even)-fatty acid intermediates by ß-oxidation 
For the final energy generation the electron transport from NADH2 and FADH2 to molecular oxygen via 
intact cytochromes is indispensable Due to the production of 2 pyruvic acid molecules from 1 glucose 
molecule the successive energy yields in the PDH- and TCAC-mediated energy-generation step from 
pyruvic acid to H2O and CO2 are 2-fold multiplied to obtain Oxidative energy generation under normal 
conditions 
The oxidative energy from glucose is generated in the next three major catabolic processes.the final 
yield Due to the serial identical production of θ molecules of acetyl-CoA from 1 palmitic acid molecule 
and the subsequent TCAC-mediated energy-generation in the step from acetyl-CoA to H2O and CO2, 
all the successive energy yields from both palmitic acid to H2O and CO2, are multiplied 8-fold 
Abbreviations PDH, pyruvate dehydrogenase, TCAC, tricarbomc acid cycle 
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The oxidative energy generation from sugars and carbohydrates other than 
glucose occurs in the same way, but only after they have been converted to 
glucose. During glycolysis, one molecule of glucose is converted to two molecules 
of pyruvic acid; in this process two molecules of ATP and two molecules of 
NADH2 are produced. TCAC is a complex biochemical system that converts 
acetyl-CoA to CO2 and H2O; in this process one molecule of GTP (equivalent to 
ATP), three molecules of NADH2 and one molecule of FADH2 are produced. 
Glycolysis and TCAC are coupled by pyruvate dehydrogenase (PDH), an enzyme 
that converts pyruvic acid, i.e., the final product of the glycolysis, to CO2 and 
acetyl-CoA; in this process one molecule of NADH2 is produced from one 
molecule of pyruvic acid. The energy stored in the energy-rich hydrogen of the 
reduced coenzymes FADH2 and NADH2 is transferred into ATP by the oxygen-
dependent "respiratory chain" (= "electron transfer system" or "cytochrome 
system"). From one molecule of NADH2 three molecules of ATP are generated, 
and from one molecule of FADH2 two molecules of ATP. Therefore, the energy 
yield of glycolysis is eight molecules of ATP per molecule glucose, of the PDH-
mediated link between glycolysis and TCAC six molecules of ATP per two 
molecules of pyruvic acid, and of the TCAC 24 molecules of ATP from two 
molecules of acetyl-CoA. Thus, the overall energy yield from one molecule of 
glucose is 38 molecules of ATP (Fig.1). 
The oxidative energy generation from fatty acids consists of two 
biochemical pathways: fatty acid ß-oxidation and the TCAC. Fatty acid ß-
oxidation implies a conversion of fatty acids (normally the C^- or the Cie-fatty 
acid, i.e. palmitic or stearic acid respectively) to 8 or 9 acetyl-CoA moieties and a 
concomitant production of one molecule of FADH2 and one molecule of NADH2 
per newly formed acetyl-CoA moiety. In the same way as the acetyl-CoA from 
pyruvic acid acetyl-CoA from fatty acids finally yields CO2, H2O and much ATP. 
Thus, the overall energy yields of palmitic acid and stearic acid are 128 and 144 
molecules of ATP, respectively. The process-specific and the overall ATP yields 
of palmitic acid are visualized in Fig.1 (cf. Table 1). The oxidative energy 
generation from amino acids is more complex, but the TCAC is involved in all 
cases. The mean energy yield from amino acids is rather high. 
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Consequences of tumor hypoxia 
The delivery of oxygen to a living cell in an organism depends on several 
conditions These include the oxygen pressure in the surroundings, the lung 
capacity in exchanging oxygen, the carrying capacity of the blood (effective 
hemoglobin concentration), the macro-circulation, the microcirculation for local 
perfusion, the tissue diffusion geometry and the ability of the cell to use oxygen 
In solid tumors the median p02 is lower than in normal tissues of the same origin 
e g , cervix tumor cells have a median p02 of 8 mm Hg versus 42 mm Hg in 
normal cervical tissue (18) Below a median tumor p02 of 10 mm Hg the mean 
ATP concentration, which reflects the sum of oxygen-independent glycolytic and 
oxygen-dependent TCAC-mediated phosphorylation, starts to drop There is, 
however, not a specific p02 threshold below which oxidative phosphorylation 
ceases This depends on the respiratory capacity of the specific cell (ι e , its 
microenvironment, mitochondria, and cytochromes) In vitro studies show that p02 
levels are critical for cells in the range of 0 5 -10 mm Hg Functions of isolated 
mitochondria are normal at p02 levels > 0 5 mm Hg, and of extracted 
cytochromes at p02 levels between 0 02 and 0 07 mm Hg The balance in the 
oxidative metabolism and the shift to the less economic anaerobic pathway in 
individual cells depends on both fast and slow mechanisms The fast mechanisms 
involve the local p02 diffusion gradients, metabolic rate and the negative 
feedback due to overproduction of intermediate products The slow mechanisms 
involve the induction of changes in the concentrations of enzymes involved in 
oxidative and anaerobic metabolism (see below) All these mechanisms together 
may account for a non-linear cessation of aerobic phosphorylation after 
diminishing the p02 in the environment of a living cell (19) 
Fermentative energy generation 
Even when TCAC is uncoupled, glycolysis can still occur This means that the 
oxygen-dependent energy generation by the PDH and the TCAC (30 molecules of 
ATP per glucose molecule) is inhibited, and that the maximal yield per glucose 
molecule can only be 8 molecules of ATP However, the energy-rich hydrogen of 
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glycolysis-related NADHa will now enzymatically be transferred to pyruvic acid 
with lactic acid as a by-product (this step 
is called "fermentation"; Fig.2). The energy content of the NADH2 molecules is not 
then all transferred into ATP molecules. The result is that one molecule of glucose 
yields only two molecules of ATP in the case of "anaerobic" glycolysis, instead of 
8 molecules of ATP as in the case of "aerobic" glycolysis. 
Lactic acid-mediated amplification of fermentation 
When the glycolytic supply of pyruvate exceeds the aerobic dissimilation of 
pyruvate, the surplus of pyruvate is reduced enzymatically at the expense of the 
concomitant surplus of NADH2 with simultaneous production of lactic acid. As 
soon as lactic acid is massively produced and not rapidly metabolized, it will lower 
the intracellular pH and thus inhibit the activity of PDH (20). In other words, the 
intracellular fermentation will increasingly uncouple the glycolysis and the TCAC. 
An important consequence is that an increasing concentration of lactic acid is 
produced as long as glucose is available. The massively produced lactic acid 
amplifies both the fermentative glycolytic lactic acid generation due to further pH-
mediated reduction of PDH activity, and thus also the uncoupling of the glycolysis 
and the TCAC. This means that, if in a tumor the amount of supplied oxygen has 
become too low for completely aerobic dissimilation, the tumor will also start 
generating energy from anaerobic dissimilation. The faster solid tumors grow, the 
more they will dissimilate in an anaerobic way. This implies that in hypoxic tumor 
areas glycolysis and TCAC are increasingly uncoupled, and that in these areas 
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Figure 2 Schematic representation regarding energy generation from glucose in the absence of 
oxygen The overall process of anaerobic dissimilation (dotted arrow) consists of two processes 
glycolysis from glucose to pyruvic acid, and fermentative conversion of pyruvic acid to lactic acid 
Fermentation occurs as soon as the TCAC is blocked This implies that the energy-rich electrons (in 
NADH2), which have arisen in glycolysis, are transferred to pyruvic acid (final product lactic acid) 
Consequently, the fermentative energy yield of glucose is 2 ATP instead of 38 ATP in aerobic 
condition (see Figure 1) 
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Energy generation in tumors 
The cellular uptake rate of relevant nutrients (i.e., both of energy-containing 
substrates, especially sugars, and of constituents of future cellular structures, 
such as amino acids) determines the growth rate of tumor cells. Increasingly 
anaerobic conditions inside tumor cells determines that energy generation by 
oxidative dissimilation of amino acids and fatty acids, and even of sugars (Table 
1), per gram tumor mass will decrease. Therefore, the energy required for tumor 
growth-related biosynthetic processes is increasingly generated by "fermentative 
glycolysis", also called "anaerobic glycolysis" or "anaerobic dissimilation" (Table 
1)-
SUBSTRATE + OXYGEN -» PRODUCTS + ENERGY 
AEROBIC DISSIMILATION 
(Ci6)-fatty acid + 23 O2 -» 16C02+16H20 
palmitic acid 
(Cie)-fatty acid + 26 O2 -> 18 CO2 + 18 H20 
stearic acid 
glucose + 6 O2 - » 6 CO2 + 6 H20 
ANAEROBIC DISSIMILATION 
fatty acid without O2 -» does not occur 
glucose without O2 -» 2 lactic acid 2 ATP 





The energy and the metabolic consequences are important. Due to the rather 
anaerobic conditions in tumor cells, the oxidative dissimilation of amino acids and 
fatty acids is reduced to nearly zero. While aerobic dissimilation results in a gain 
of 38 molecules of ATP per molecule of glucose, anaerobic dissimilation only 
yields 2 molecules of ATP per molecule of glucose (and 2 molecules of [energy-
rich] lactic acid). 
Metabolism 
In general, a human being on a normal diet has a 2:1 intake of carbohydrates and 
fats, respectively, on a weight basis. The main energy source of a living 
mammalian cell is the oxidative metabolism of glucose and fatty acids. Amino 
acids will deliver energy only after transformation into glucose by 
gluconeogenesis in the catabolic status or after over-consumption of protein (21). 
Some tissues, like the brain and bone marrow, depend merely on glucose 
metabolism. Nevertheless, under aerobic conditions the majority of cells will 
simultaneously metabolize 3 molecules of glucose and 1 molecule of fatty acid 
(this roughly means 2:1 on weight basis). Three molecules of glucose plus one 
molecule of palmitic acid deliver (3 χ 38 plus 1 χ 128) molecules of ATP, i.e. 242 
molecules of ATP. Without oxygen the mammalian cell cannot metabolize fatty 
acids and thus depends on anaerobic degradation of merely glucose. 
Fermentation of 1 molecule of glucose delivers 2 molecules of ATP and 2 
molecules of lactic acid. Thus, for the same energy production of 242 molecules 
of ATP the cell has to ferment 121 molecules of glucose and will produce 242 
molecules of lactic acid. In other words, anaerobic metabolism depends on 
glucose only and needs about 40 times the amount of glucose molecules that is 
used under aerobic conditions for the same energy production (see Introduction). 
This increased need for glucose will switch on gluconeogenesis. 
Tumor-associated gluconeogenesis 
Since tumors are continuously growing, they increasingly divert glucose from 
tissue and organ cells. Since only a small part of the lactic acid is excreted, 
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(hepatic) gluconeogenesis must be switched on in order to remove the lactic acid 
and to assure the availability of glucose for energy generation inside the various 
tissue and organ cells This salvage process means that (at a high rate) one 
molecule of glucose is produced from two molecules of lactic acid Hepatic 
gluconeogenesis is part of the cyclic process known as the Con cycle. This cycle 
implies that if in human tissues or tumors glucose is anaerobically metabolized, 
the formed lactic acid is transported to the liver for renewed synthesis of glucose 
Thus, gluconeogenesis appears to mask anaerobic dissimilation of glucose, and 
consequently, reduces the diagnostic value of serum glucose and lactate Raised 
concentrations of glucagon and the glucocorticoid, Cortisol, and lowered insulin 
concentrations are indicative for induced gluconeogenesis 
An important characteristic of gluconeogenesis is that the renewed 
synthesis of glucose out of lactic acid is energetically much more difficult than the 
degradation of glucose to lactic acid it does not yield energy, but requires energy 
Whereas anaerobic dissimilation yields two molecules of ATP per molecule of 
glucose, the renewed synthesis of glucose from lactate requires six molecules of 
ATP Even if the energy yield from anaerobic dissimilation is not involved in tumor 
growth, the net result is a deficit of four molecules of ATP per re-synthesized 
molecule of glucose Normally the deficit will be six molecules of ATP This 
energy required for gluconeogenesis is aerobically produced in the liver and 
means that additional substrates such as sugars, fatty acids and/or ammo acids, 
must aerobically be dissimilated 
Tumor-associated increase of temperature 
Since the fermentation of glucose to lactic acid yields two molecules of ATP, it 
might be expected that for gluconeogenesis the same amount of ATP would be 
required However, it is an important characteristic of gluconeogenesis that it 
requires six molecules of ATP for the re-synthesis of glucose from lactic acid, ι e , 
four additional molecules of ATP The energy from these four molecules is lost 
inside the liver during three subsequent steps of gluconeogenesis (Fig 3) 
This energy is then dissipated as heat energy inside the watery environment of 
the hepatic gluconeogenetic cells, transferred to the blood stream and thus 
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spread throughout the whole body; it may cause sub-febrile temperature or 
sometimes even fever. In cachectic patients the increased temperature is often 
seen as nightly sweating. This also means that this heat energy is derived from 
the metabolic energy that is produced in the liver by aerobic dissimilation from 
substrates such as sugars, fatty acids and/or amino acids. The origin of these 
substrates is discussed later. 
A constant dietary pattern usually means a constant body weight. In cancer 
patients with a continuously active gluconeogenesis, proteins and lipids are 
increasingly withdrawn from non-tumor tissues. This is the basis of cachexia. 
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Figure 3 (next page) 
Schematic representation of the essential processes in both the intracellular anaerobic dissimilation in 
the tumor (at the left from top to bottom) and (after hematogenous transport of lactate) hepatic 
gluconeogenesis (at the right from bottom to top). Together these two processes constitute the Cori-
cycle. With regard to the metabolites, the pathways seem to be nearly the same (the difference 
concerns the oxaloacetate), but they are not. The common reversible processes are indicated with the 
characters a. to h (see below), but not bio-chemically specified. The essential differences between 
glycolysis and gluconeogenesis are specified at the metabolic sites 1, 2 and 3; these processes 
represent irreversible biochemical processes. From anaerobic dissimilation a net energy yield of 2 
ATP is generated. During gluconeogenesis energy must be invested (since the energy content of GTP 
is equivalent to one of ATP, the net yield is -6 ATP). One cycle of the Con-cycle costs 4 ATP (net yield 
is -4 ATP). At three specific gluconeogenetic sites (1: conversion of pyruvate to PEP; 2: conversion of 
fructose-1,6-diP to fructose-6-P; 3: conversion of glucose-6-P to glucose) energy is dissipated. 
Chemical bonding energy is converted to heat energy, which is transferred to the surrounding water 
molecules. The heat created inside the liver is hematogeneously transported through the whole body 
where it may create a rise in body temperature 
The characters represent a., phosphoglucose-isomerase, b.: aldolase, c: tnosephosphate isomerase, 
d.: glycerinaldehyde-3-phosphate dehydrogenase (= GAP-DH), e.: phospho-glycerate kinase, f: 
phosphoglycerate mutase, g.: enolase, and h.: L-lactate dehydrogenase (= (L-) LDH). The symbol P, 
means inorganic phosphate. 
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Cancer cachexia 
The Cori cycle is essential for cachexia. The more the tumor dissimilates in an 
anaerobic way, the more additional substrates (from food) are required by the 
liver for aerobic energy generation in favor of gluconeogenesis. From the moment 
the food uptake capacity becomes the limiting factor, the liver will also dissimilate 
substrates, such as fatty acids and amino acids, which originate from structural 
components of body tissues. As a consequence loss of body weight, the first step 
of cachexia, begins. Hormones involved in gluconeogenesis aggravate this by 
activating muscle cell breakdown of proteins and fat cells to release fatty acids 
(22,23). 
From the moment tumor cells start the anaerobic dissimilation the 
increasing glucose demand can only be met by accelerated hepatic 
gluconeogenesis, which is fed with lactate derived from either glucose or 
glycogenic amino acids. The hepatic synthesis of glucose from tissue lactate has 
been shown to be significantly more active in weight-losing cancer patients. In 
these patients decreased glucose and insulin levels, as well as increased 
glucagon, growth hormone and Cortisol levels have been found, which point at an 
increasing glucose demand and accelerated gluconeogenesis. Whereas the 
tumor deprives the host of available glucose, which is either extracted from food 
or glycogen, or synthesized from glucose- or amino acid-derived lactate, the other 
parts of the body, the liver included, have to rely mainly on the aerobic 
dissimilation of fatty acids. This may lead to loss of body fat and to 
gluconeogenesis-induced loss of muscle tissue, and eventually to cancer-induced 
cachexia (Fig. 4). 
154 
Figure 4 (next page) 
Schematic representation of the flow of metabolic energy in cancer patients (see also text) 
Compartment A the tumor 
From the moment the growing tumor has shifted the energy generation from aerobic to 
anaerobic dissimilation of glucose due to a too low oxygen supply, it increases glucose 
consumption and simultaneously lactate production 
Compartment Β the liver (for details of the Con-cycle see Fig 3) 
The consequences of increased lactate production can be met by an accelerated hepatic 
gluconeogenesis, which synthesizes 1 molecule of glucose from 2 molecules of lactate and 
additional energy The required energy (6 ATP) is produced by the aerobic dissimilation of 
energy-rich metabolites (fatty acids and deammated ammo acids) 
Compartment C the body tissues 
Due to low serum levels of ammo acids and fatty acids because of hepatic gluconeogenesis, 
fats are released from the body fat stores and saponified to yield energy-rich fatty acids and 
glycerol, and proteins (especially m muscles) are released, hydrolyzed and the produced 
ammo acids deammated 
Compartment D the gastrointestinal tract (and food intake) 
Carbohydrates/ sugars, fats/ fatty acids and proteins/ amino acids are the primary 
sources of human energy. The gastrointestinal tract is responsible for adequate 
food intake. Tumors may interfere directly with gastrointestinal function by 
obstructing the lumen or its vessels, by affecting its nerve functions, or by 
diminishing the production of digestive juices, and indirectly via hepatic or kidney 
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Discussion 
This hypothesis is the third step in an attempt to understand the main relation 
between cancer and cachexia (3,4) on the basis of the Cori-cycle. The important 
new aspects are the role of fatty acids, the lactic acid-mediated reduction of PDH 
activity and the gluconeogenetic energy dissipation. It is emphasized that this 
hypothesis reflects only the main energy flow and not the many factors, e.g., 
cytokines, such as tumor necrosis factor (TNF), interleukin (IL)-1 and IL-6, 
uncoupling proteins (UCPs), lipid-mobilizing factor (LMF) and proteolysis-inducing 
factor (PIF), that anyhow control and/ or regulate this flow. 
The main cause of weight loss is massive hepatic gluconeogenesis due to 
tumor-induced lactic acid production caused primarily by the switch from aerobic 
to increasingly anaerobic dissimilation in the tumor. This new concept opens new 
ways for treatment. For instance, if the supply of molecular oxygen into the tumor 
is increased, tumor-induced lactic acid production will decrease, and thus also the 
weight loss. From this point of view, increasing the hemoglobin level, for instance 
by erythropoietin may be suitable for reducing cancer cachexia (24). 
The final scheme (Fig 4) represents many essential aspects regarding cancer and 
cachexia. It may also be used as a starting point for links to other cancer-related 
items, e.g., fatigue. The advantage is that several relevant interrelationships are 
already indicated. Tuberculosis-associated cachexia resembles tumor-associated 
cachexia in many aspects. The effect of the aerobic intracellular mycobacteria is 
thought to be similar to the effect of uncontrolled growth of tumor cells: due to the 
mycobacterial oxygen consumption the intracellular oxygen level in infected cells 
will become too low and consequently lactic acid production starts. It is strongly 
suggested that the association between cachexia and many chronic and end-
stage diseases (1) is fundamentally the same as described for cachexia and 
cancer. 
Acknowledgement 




1 Tisdale MJ. Cachexia in cancer patients. Nature Rev Cancer 2002; 2: 862-71. 
2 Tisdale M J. Biology of cachexia. JNC11997; 89: 1763-73. 
3 Gold J. Proposed treatment of cancer by inhibition of gluconeogenesis. 
Oncology 1968; 22: 185-207. 
4 Dills WL. Nutritional and physiological consequences of tumour glycolysis. 
Parasitology 1993; 107: S177-86. 
5 Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. 
6 Michalides R. Cell cycle reulators: mechanisms and their role in aetiology, 
prognosis treatment of cancer. J Clin Path 1999; 52: 555-68. 
7 Koea JB, Shaw JHF. The effect of tumor bulk on the metabolic response to 
cancer. Ann Surg 1992; 215: 282-8. 
8 Costa G, Lane WW, Vincent RG, Siebold JA, Aragon M, Bewley PT. Weight 
loss and cachexia in lung cancer. Nutr Cancer 1980; 2: 98-103. 
9 Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nature Rev 
Cancer 2002; 2: 38-47. 
10 Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic 
and molecular aspects. J Natl Cancer Inst 2001 ; 93: 266-76. 
11 Jerusalem G, Hustinx R, Béguin E, Fillet G. The value of positron emission 
tomography (PET) imaging in disease staging and therapy assessment. Ann 
Oncology 2002; 13 Suppl 4: 227-34. 
12 Holm E, Hagmüller E, Staedt U. Substrate balances across colonic 
carcinomas in humans. Cancer Res 1995; 55: 1373-8. 
13 Holroyde C, Gabuzda TG, Putnam RC, Paul P, Reichard GA. Altered glucose 
metabolism in metastatic carcinoma. Cancer Res 1975; 35: 3710-4. 
14 Holroyde CP, Axelrod RS, Skutches CL, Haff AC, Paul P, Reichard GA.. 
Lactate metabolism in patients with metastatic colorectal cancer. Cancer Res 
1979;39:4900-4 
15 Holroyde CP, Skutches CL, Boden G, Reichard GA.. Glucose metabolism in 
cachectic patients with colorectal cancer. Cancer Res 1984; 44: 5910-3. 
16 Roh MS, Ekman L, Jeevanandum M, Brennan MF. Gluconeogenesis in 
tumor-influenced hepatocytes. Surgery 1984; 96: 427-34. 
158 
17 Vaupel Ρ, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, 
and metabolic microenvironment of human tumors: a review. Cancer Res 
1989;49:6449-65. 
18 Höckel M, Schienger Κ, Aral Β, Milze Μ, Schaffer U, Vaupel P. Association 
between tumor hypoxia and malignant progression in advanced cancer of the 
uterine cervix. Cancer Res 1996; 56: 4509-15. 
19 Höckel M, Vaupel P. Biological consequences of tumor hypoxia. Sem 
Oncology 2001 ; 28 Suppl 8: 36-41. 
20 Luft FC. Lactic acidosis update for critical care clinicians. J Am Soc Nephrol 
2001; 12:S15-9. 
21 Lowry SF, Foster DM,Norton JA, Berman M, Brennan MF. Glucose disposal 
and gluconeogenesis from alanine in tumor-bearing fischer 344 rats. JNCI 
1981;66:653-8. 
22 Inculet RI, Peacock JL, Gorschboth CM, Norton JA. Gluconeogenesis in the 
tumor-influenced rat hepatocyte: importance of tumor burden, lactate, insulin 
and glucagon. JNCI 1987; 79: 1039-46. 
23 Cersosimo E, Pisters PWT, Pesola G, Rogatko A, Vydelingum Ν A, 
Bajorunas D, Brennan MF. The effect of graded doses of insulin on peripheral 
glucose uptake and lactate release in cancer cachexia. Surgery 1991 ; 109: 
459-67. 
24 Van Halteren HK, Bongaerts GPA, Verhagen CAM, Kamm YJL, Willems JL, 
Grutters GJ, Koopman JP, Wagener DThJ. Recombinant human 
erythropoietin attenuates weight loss in a murine cancer cachexia model. J 




RECOMBINANT HUMAN ERYTHROPOIETIN ATTENUATES WEIGHT 
LOSS IN A MURINE CANCER CACHEXIA MODEL 
H.K. van Halteren1, G.P.A. Bongaerts2, C.A.M. Verhagen1, Y.J.L. Kamm1, J.L 
Willems3, G. J.Grutters4, J.P. Koopman4, D.Th.J. Wagener1 
(1) Department of Medical Oncology, University Medical Center, Nijmegen, the 
Netherlands 
(2) Department of Medical Microbiology, University Medical Center, Nijmegen, the 
Netherlands 
(3) Department of Clinical Chemistry, University Medical Center, Nijmegen, the 
Netherlands 
(4) Central Animal Laboratory, University of Nijmegen, the Netherlands 
This study was financially supported by a grant from Ortho Biotech , a division of 
Janssen Cilag BV, Tilburg, the Netherlands 
Published in: 
J Cancer Res Clin Oncol 2004; 130: 211- 6 
161 
ABSTRACT 
Background: Within hypoxic tumor regions anaerobic dissimilation of glucose is 
the sole source of energy generation. It yields only 5% of the ATP that is normally 
gained by means of oxidative glucose catabolism. The increased need for 
glucose may aggravate cancer cachexia. We investigated the impact of 
recombinant human erythropoietin (RhEPO) and increased inspiratory oxygen 
concentrations on weight loss in tumor bearing mice. 
Methods: Fragments of the murine C26-B adenocarcinoma were implanted in 
60 BALB/c-mice. The mice were divided into 4 groups and assigned to: (A) no 
treatment, (B) RhEPO- administration ( 25 ID daily from day 1-11, 3 times per 
week from day 12), (C) RhEPO and 25% oxygen, (D) RhEPO and 35% oxygen. 
Three control groups of 4 healthy mice each received the same treatment as 
groups A,B, and D, respectively. Hematocrit and hemoglobin levels, tumor 
volume, and body weight were monitored. At day 17 the experiment was 
terminated and the lactate concentration was measured. The tumors were 
excised and weighed and, for each mouse, the percentage weight loss was 
calculated. The impact of tumor weight and the treatments on lactate 
concentration and weight loss was evaluated. 
Results: Significant positive correlations were found between tumor weight and 
lactate concentration and between tumor weight and percentage weight loss. In 
the mice with the largest tumors, RhEPO displayed a significant weight loss-
reducing effect, and a significant negative correlation was found between 
hemoglobin concentration and weight loss. An oxygen-rich environment did not 
appear to influence weight loss. 
Conclusion: Anaerobic glycolysis in a growing C26-B tumor is related to weight 
loss. RhEPO administration results in a reduction of the percentage weight loss; 
this effect is probably mediated by an increased hemoglobin concentration. 
Introduction 
In cancer patients cachexia is a very serious problem which affects quality of life 
and disease treatability. It is supposed to be caused by an acute phase reaction 
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initiated by host and/or tumor. The most important substances identified so far are 
proteolysis-inducing factor ( PIF) and the MAC16-factor which induces lipolysis1"9. 
In our opinion the importance of tumor hypoxia and gluconeogenetic energy 
dissipation as a cause of cancer cachexia should also be underlined. In the past 
35 years many studies have revealed the parasitic nature of a tumor. It requires a 
substantial amount of energy for its continuous growth. The amount of energy 
released by catabolism of glucose, fatty acids, or amino acids is maximal in the 
presence of abundant molecular oxygen ( aerobic catabolism), but minimal in its 
absence ( Table 1). Anaerobic catabolism of glucose generates only 5 % of the 
energy yielded by aerobic catabolism of glucose. The final product is lactate, 
rather than the carbon dioxide and water that are produced under aerobic 
conditions. Holm et al. have previously found up to 43-fold increased lactate 
concentrations in the draining vein of a human colorectal carcinoma in 
comparison with the femoral vein, which proves that the anaerobic catabolism of 
glucose is an important energy source10. If the oxygen supply to the tumor 
remains constant in the presence of an ever-increasing tumor mass, oxygen 
becomes the limiting factor of energy generation inside the growing tumor. Under 
aerobic conditions a mammalian cell will metabolize equicaloric amounts of 
glucose and fatty acids. Under anaerobic conditions it completely depends on 
glucose fermentation, because it cannot ferment fatty acids. Hence, tumor cells 
will need to consume at least 40 times more glucose to generate an equal amount 
of energy as under aerobic conditions from normal dietary glucose and fatty acids 
just to survive. Thus, a tumor with hypoxic areas requires more glucose for the 
maintainance of its growth. Once the alimentary intake is insufficient to provide 
the required amount of glucose, additional glucose is synthesized by hepatic 
gluconeogenesis. Whereas the anaerobic generation of 2 moles of lactate from 1 
mole of glucose yields 2 moles of ATP ( anaerobic glycolysis), the regeneration of 
1 mole of glucose from 2 moles of lactate ( gluconeogenesis) requires 6 moles of 
ATP. This cyclic process of anaerobic glycolysis and gluconeogenesis, which is 
called the Cori cycle, has been shown to be significantly more active in cachectic 
patients than in non-cachectic controls11"13. The additional energy (6 ATP per 
mole glucose) which is required to keep the Cori cycle functioning is produced in 
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the liver by aerobic catabolism of fatty acids and amino acids. Due to the 
continuous character of this process body fat and muscle proteins are lost, which 
leads to weight loss. 
We hypothesized that interventions aimed at improving tumor oxygenation may 
attenuate weight loss. In the present murine cancer cachexia model we evaluated 
the effect of erythropoietin administration under room air conditions or in 
combination with higher inspiratory oxygen concentrations on weight loss. 
MATERIALS AND METHODS 
The Murine Cancer Cachexia Model System 
Female BALB/c-mice of 10 weeks age were placed in equal cages with a feeding 
system which allowed the measurement of daily ingested food ( RMH-B-chow. 
Hope Pharms BV, Woerden, the Netherlands). With some extra applications the 
inspiratory oxygen concentration within the cage could be increased up to 40% 
without serious changes in air humidity. At day 0 of the experiment a vital 
fragment ( approximately 2 mm in diameter) of the murine adenocarcinoma C26-
B ( G. Peters, Free University Hospital, Amsterdam, the Netherlands) was 
implanted subcutaneously in the right flank of each mouse. In the mice assigned 
to treatment with Epoetin Alfa ( RhEPO, Ortho Biotech, Tilburg, the Netherlands) 
daily subcutaneous injections of 25 units RhEPO, diluted with 0.1 ml phosphate 
buffered saline, were given from day 1 until day 1114. From day 12 on the dose 
was decreased to 25 units three times a week. The amount of ingested food was 
measured daily in all cages. Every 2 days the body weight and tumor volume of 
all mice were measured. At day 0, 10 and the day before study termination a 
small amount of blood was taken from each mouse by an orbital puncture for the 
measurement of the hematocrit and the hemoglobin concentration ( l-stat 
cartridges, Abbott Diagnostic Division, Chicago, USA). Prior to the tumor 
implantation and the blood withdrawals the mice were sedated by isoflurane 
inhalation. At the end of the study all mice were killed by decapitation. During this 
procedure 0.5 ml of blood was collected in a tube with perchloric acid for 
determination of the L-lactate-concentration ( Cobas Mira Plus; Roche 
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Diagnostica, Basel, Switzerland). The tumors were removed and weighed. The 
relation between tumor weight, lactate concentration and % weight loss was 
evaluated. 
Definition of percentage weight loss 
From an earlier pilot study we knew that the tumor-bearing mice usually reached 
their maximal body weight at about the 10th day. At this time the tumor size was 
very limited in relation to total body weight. In the subsequent days a short-lasting 
decrease in body weight was registered which was followed by an increase in 
body weight due to the fastly growing tumor. At the day of sacrification the tumor 
comprised a considerable percentage of the total body weight. In order to correct 
for this phenomenon the % weight loss was defined as: 
100 ( 1 - tumor-free body weight at the day of sacrification) 
maximal body weight 
Study design 
Sixty mice were assigned to 1 of 4 experimental groups: (A) no treatment; (B) 
RhEPO-administration according to the study protocol under room air conditions; 
(C) RhEPO and 25% normobaric oxygen; (D) RhEPO and 35% normobaric 
oxygen. Three groups of 4 tumor-free mice served as controls for group A, Β and 
D. The study protocol had been approved by the local animal ethics committee. 
Statistics 
For the comparison between groups the data were presented as mean + the 
standard deviation. The significance of a difference in distribution between two 
groups was calculated by means of the 2-sided students't-test. P-values below 
0.05 were considered significant. Scatter diagrams were made for sets of 
variables which were thought to be related. The magnitude of a correlation - the 
correlation coefficient ( r) - was calculated by means of the two-tailed Pearson 
test. This implies that the correlations were considered to be linear. For all 
statistical evaluations the SPSS 9.0 for windows-software was used. 
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Results 
The study was terminated at the 17th day. At the 15th and 16th day 8 mice had 
been bitten in their tumor by fellow mice, which had led to death in 6 cases. This 
problem occurred in all 4 experimental groups. The hemoglobin concentration-
measurement scheduled for day 21 was performed at day 16 and all wounded 
mice had to be excluded from further analyses. Therefore, the final analysis 
included 52 tumor-bearing mice and 12 healthy controls.The daily food intake per 
mouse was considerably lower in the tumor-bearing mice ( 2.1 grams) than in 
their healthy controls ( 3.1 grams). RhEPO administration resulted in a clear 
increase in hemoglobin level (table 1). 
Assigned treatment 
Room air 
RhEPO + room air 
RhEPO + 25% O2 
RhEPO + 35% 0 2 
DavO 
0.41 + 0.02 
0.42 + 0.01 
0.42 + 0.01 
0 41 +0.01 
Mean hematocrit 
( + standard deviation) 
Day 9 
0 42 + 0.01 
0.57 + 0.01 
0.56 + 0.02 
0.55 + 0.02 
Day 16 
0 42 + 0.02 
0 53 + 0.02 
0.52 + 0.03 
0.53 + 0.03 
Table 1. Cancer cachexia model encompassing 52 female BALB/c-mice with a C26-B 
adenocarcinoma: changes in hematocrit values during the experiment according to treatment group ( 
RhEPO = recombinant human erythropoietin). 
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The median tumor weight at day 17 was 1.3 grams and there was no significant 
difference in tumor weight between the 4 treatment groups ( figure 1). 
In the tumor-bearing mice a significant positive correlation between tumor weight 
and serum lactate concentration was found (figure 2, correlation coefficient + 
0.683, p< 0.001). There was also a significant positive correlation between tumor 
weight and percentage weight loss ( figure 3, correlation coefficient + 0.744; p< 
0.001). For a given tumor weight the % weight loss appeared higher in untreated 
mice than in RhEPO-treated mice. If the entire group of 52 tumor-bearing mice 
was divided in two according to tumor weight (median or less versus more than 
median) weight loss appeared more severe in untreated mice than in the 
corresponding RhEPO treated animals ( table 2). Only in the mice with the 
highest tumor weight this difference reached significance ( P<0.001). In these 26 
mice a significant negative correlation between hemoglobin concentration and % 
weight loss was found ( figure 4, correlation coefficient - 0.643, p= 0.001). Higher 
inspiratory oxygen levels did not appear to enhance the effect of RhEPO on 
weight loss. 
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Assigned treatment Mean % weight loss + SD Mean lactate 
concentration 
+ SD ( mmol/L) 
Healthy controls/ no tumor 2 93 ± 0 61 (n=12) 
No therapy ( n= 4) 
RhEPO ( n= 4) 




Tumor weight < 1 3 grams 2 65 + 0 79 ( n= 26) 
No therapy ( n=9) 
RhEPO ( n= 4) 
RhEPO + 25% 02 ( n= 6) 
RhEPO + 35% O2 ( n= 7) 
132 + 82 
122 + 34 
127 + 45 
116 + 38 
Tumor weight > 1 3 grams 3 96 ± 0 90 ( n= 26) 
No therapy ( n= 5) 
RhEPO (n= 10) 
RhEPO + 25% 0 2 ( n= 9) 
RhEPO + 35% O2 ( n= 2) 
27 2 + 2 7 
198 + 34 
196 + 52 
190 + 57 
SD = standard deviation 
'Student f test, P< 0 001 
Table 2 Cancer cachexia model encompassing 52 female BALB/c-mice with a C26-B 
adenocarcinoma percentage weight loss and serum lactate concentration according to tumor weight 
and assigned treatment 
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Figure 1. Cancer cachexia model encompassing 52 female BALB/c-mice with a C26-B 
adenocarcinoma: mean tumor weight and 95% confidence interval ( CI) according to assigned 
treatment. 1= no treatment. 2= erythropoietin ( RhEPO) and room air. 3= RhEPO and 25 % oxygen. 























Figure 2. Relation between tumor weight and serum lactate concentration in 52 female BALB/c-mice 
with a C26-B adenocarcinoma who had or had not been treated with recombinant human 
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Figure 3. Relation between tumor weight and percentage weight loss in 52 female BALB/c-mice with a 
C26-B adenocarcinoma who had or had not been treated with recombinant human erythropoietin ( 
RhEPO). 
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Figure 4. Cancer cachexia model encompassing 52 female BALB/c-mice with a C26-B 
adenocarcinoma; Relation between hemoglobin concentration and percentage weight loss in the 26 
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Discussion 
This study was performed to get support for the hypothesis that inefficient 
anaerobic glycolysis within a growing tumor aggravates cancer cachexia. We had 
chosen a tumor with a high mitotic rate, because such a tumor was expected to 
become hypoxic in an early stage and may impose the largest pressure on the 
metabolic compensating systems of the body. At termination of the study the 
median tumor weight was 1.3 gram, approximately 6% of the total body weight. 
The lactate levels of tumor-free controls and mice with a tumor weight less than 
1.3 grams did not differ, which illustrates the compensating potency of an 
enhanced Cori cycle. In the mice with heavier tumors the Cori cycle could not 
compensate the increased lactate production. These mice had a higher lactate 
concentration and displayed more weight loss. Apparently, the rate of anaerobic 
glycolysis increases in case of a faster tumor growth rate and this subsequently 
results in increased host catabolism. The application of the Pearson test to the 
scatter diagrams may proof in time to be an oversimplification. To date, there are 
however no findings which warrant another statistical calculation. 
RhEPO appeared to attenuate weight loss in all tumor bearing mice. Higher 
concentrations of normobaric oxygen did not enhance this effect, probably 
because the hemoglobin content was the limiting factor for oxygen transportation 
in the blood and improved tumor oxygenation was not achieved. Hyperbaric 
oxygen may have proved more effective. The mean daily intake in the untreated 
tumor-bearing mice was 2.3 grams and in the RhEPO-treated groups 2.1 grams. 
The weight loss-reducing effect of RhEPO could therefore not be attributed to a 
higher food intake. Could it be explained by an improvement in tumor 
oxygenation? Several preclinical studies have shown that the tumor oxygenation 
can be improved by intravenous administration of a hemoglobin solution15"17. 
Kelleher et al. have previously reported an improved tumor oxygenation in anemic 
Sprague Dawley rats with a DS sarcoma who were treated with RhEPO18. Becker 
et al. have found a relation between anemia and increased tumor hypoxia in 
patients with head and neck squamous carcinomas19. In our study the mice were, 
however, not anemic and RhEPO administration resulted in an elevated 
hemoglobin concentration. We do not know whether this concentration was 
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optimal with regards to tumor oxygenation. The optimal concentration depends on 
tumor size and quality of vasculature, which has been clearly illustrated by a 
study in human gynecological cancers by Vaupel et al.20 
The weight loss reducing effect of RhEPO may also have been exerted by 
another mechanism. The tumors removed in our study displayed intensive 
erythropoietin receptor expression. Upregulation of erythropoietin receptor 
expression has been found in hypoxic breast cancer cells21,22. This upregulation 
may be aimed at preservation of cell function under hypoxic conditions, which has 
already proved true for brain tissue23. In this way RhEPO may also have 
diminished the hypoxic tumor fraction and reduced weight loss. Some 
investigators have provided in vitro-evidence for a tumor growth-promoting effect 
of RhEPO21,22. There are however no in vivo-studies which support this. Like us, 
Kelleher et al. did not find a growth-increasing effect of RhEPO18. 
In cancer patient care RhEPO is regarded as an agent which can decrease the 
need for blood transfusions and improve the patients' quality of life24"27. This 
improvement in quality of life is supposed to be a direct consequence of the 
raised hemoglobin concentration. It may however also reflect reduced weight 
loss. Two patient studies which have been carried out for other purposes support 
this hypothesis. Daneryd et al. randomised 108 weight-losing patients with 
advanced cancer to treatment with either indomethacin or RhEPO and 
indomethacin. During follow up the RhEPO-treated patients had significantly less 
weight loss and a significantly more preserved exercise capacity28. Csâki et al. 
randomised 15 children who were undergoing chemotherapy for different solid 
tumors to either treatment with RhEPO or no treatment. Two trends were seen: in 
the RhEPO-treated group the weight loss was more limited and the performance 
status better preserved29. 
In conclusion, the results of our murine cancer cachexia model strongly support 
the hypothesis that anaerobic dissimilation within a growing tumor is an important 
factor which facilitates cachexia. RhEPO-administration attenuates weight loss, 
possibly by an improvement in tumor oxygenation. 
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Treatment of localized colorectal cancer 
Surgery 
Total mesorectal excision (TME) is the standard surgical procedure for rectal 
cancer. 
A newer technique is transanal endoscopic microsurgery ( TEM), which allows 
minimally invasive full-thickness local excision of rectal tumors with perirectal fat 
dissection. Such a procedure preserves anal sphincter function with positive 
consequences for quality of life. The procedure is considered safe for patients 
with T1-tumors ( as estimated by means of ultrasonography). In case of deeper 
tumor infiltration TEM should be combined with radiotherapy, but such 
multimodality treatment needs further study before it can be introduced in general 
practice. 
Laparoscopic resection of colon cancer is another novel surgical procedure. Small 
single-center studies suggest that such a procedure is safe when performed by 
an experienced surgeon. Like TME, it should be evaluated in larger prospective 
randomized studies to determine its value. 
The decrease in immunologic defence due to colorectal cancer surgery, which 
could be in favour of remaining micrometastases, used to be a hot topic. It was 
hypothesized that substances, such as Granulocyte/ Monocyte- Colony 
Stimulating Factor, could induce an immunologic reaction against 
micrometastases by recruitment of antigen-presenting cells. Up to now, there are 
however no studies which have provided clinically relevant results. But this new 
approach warrants further investigation. 
Radiotherapy 
The radiotherapy schedule has probably not reached its most optimal shape. 
Attention should be paid to the tumor environment and its repercussions on 
radiotherapy efficacy. Innovations of the MRI technique with new vascular agents 
are expected in the near future, which will enable better tumor localization. 
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Complications due to radiotherapy, such as radiation enteritis, will probably occur 
less often with this new technique. 
An improvement in tumor oxygenation with carbogen may lead to an increased 
radiotherapy response, as has already been shown in patients with head and 
neck cancer. The efficacy of radiotherapy could be further enhanced by the 
administration of substances, which render tumor cells more sensitive to 
irradiation (radiosensitizers). 5-fluorouracil, capecitabin, irinotecan and oxaliplatin 
have all proved to be radiosensitizers and the most optimal chemoradiation-
schedule is still to be found in large randomized trials. In preclinical models, 
Cyclooxygenase-2( COX-2)-inhibitors, such as celecoxib, and the epidermal 
growth factor receptor-inhibitor cetuximab have also shown radiosensitizing 
abilities and should be studied in further detail. 
Adjuvant chemotherapy 
The indication field for adjuvant chemotherapy will probably become larger. 
The group of patients expected to benefit from adjuvant chemotherapy needs to 
be redefined. Apart from Dukes stage, genotypical ( analyzed with the micro-array 
assay) and phenotypical tumor properties known to influence prognosis, should 
determine which colon cancer patients should receive adjuvant chemotherapy. 
The presence of minimal residual disease in bone marrow could also be a useful 
parameter for the determination of recurrence risk. 
Because of its easy way of administration capecitabin, an oral fluoropyrimidine, 
will probably become the agent of choice for adjuvant chemotherapy. In the near 
future, pharmacogenomics ( the science that uncovers genetic properties of tumor 
and host which are related to treatment efficacy and toxicity) may enable us to 
foresee whether a tumor will respond to fluoropyrimidines or irinotecan. This will 
give us the opportunity to prescribe tumor-tailored chemotherapy. 
Adjuvant chemotherapy is also expected to prolong survival in rectal cancer 
patients and a Dutch randomized prospective trial ( the PROCTOR study) is 
underway. 
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Treatment of metastasized colorectal cancer 
Limited metastatic disease 
In case of a limited number of isolated hepatic or pulmonary metastases there is 
no doubt that surgery strongly improves prognosis. Phase ll-studies have shown 
that a considerable percentage of patients with unresectable liver metastases 
could undergo resection after succesful neoadjuvant chemotherapy. The 
therapeutical value of neoadjuvant and adjuvant chemotherapy should be further 
tested in randomized prospective phase Ill-trials. Fluorine magnetic resonance 
spectroscopy of the liver, a non-invasive tool for prediction of capecitabin efficacy 
and toxicity, could be very useful for multimodality treatment of isolated liver 
metastases. 
Radiofrequency ablation offers the opportunity of local treatment for unresectable 
liver metastases.In a very interesting EORTC (CLOCC)-study the additive value 
of radiofrequency ablation will be tested in patients with unresectable liver 
metastases who are about to receive palliative chemotherapy. 
Extensive metastatic disease 
Capecitabin, irinotecan and capecitabin/oxaliplatin are nowadays considered as 
the three standard lines of palliative chemotherapy. However, not all patients with 
extensive metastatic disease stay fit enough during their disease course to 
receive all three regimens. If the first two lines are combined, the treatment 
sequence can be limited to two lines and more patients may complete the entire 
treatment sequence. This may subsequently lead to an improved overall survival. 
In order to evaluate this hypothesis the Dutch Colorectal Cancer Group has 
initiated a randomized prospective study. The results are eagerly awaited. 
As also mentioned in the adjuvant chemotherapy-session, pharmacogenomics is 
expected to play a central role in future palliative chemotherapy. 
Another important question concerns the duration of palliative chemotherapy: 
should therapy be continued until progression or should it be given for a standard 
period and restarted in case of progression? A no therapy-period may improve 
overall quality of life, but it should not shorten disease-free and overall survival. A 
well-designed randomized prospective study should provide us with the answer. 
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A promising new drug is the epidermal growth factor receptor ( EGFR)-antagonist 
cetuximab. Treatment results are optimal when it is combined with irinotecan and 
responses also occur in irinotecan-resistant tumors. The response rate of about 
30% which has been reported in phase ll-studies has however only been 
achieved in patients with an EGFR-positive tumor. A phase Ill-study, in which 
cetuximab and irinotecan in fourth line are compared with best supportive care, is 
needed. 
Another promising family of drugs are the COX2-inhibitors, such as celecoxib, 
which have originally been developed as pain killers. They however also bind to 
COX-2-receptors in the tumor. In preclinical studies COX-2 inhibitors enhance the 
cytotoxic effect of chemotherapy by means of several mechanisms, for instance 
by restoration of the tumor cell capacity to become apoptotic. 
Supportive care 
Supportive care must and will receive more scientific appraisal in the future. This 
thesis focussed on some clinical implications of anemia and tumor hypoxia. 
Anemia may lead to more agressive tumor behaviour 
The preoperative hemoglobin concentration should be recorded in randomized 
prospective studies on adjuvant chemotherapy and/or radiotherapy to determine 
whether preoperative anemia is related with a poorer survival. If this proves to be 
the case, the effect of anemia correction on survival should be studied. 
Anemia may enhance tumor hypoxia and facilitate weight loss 
Our study suggested that blood boosting with erythropoietin (EPO) leads to less 
weight loss in cancer bearing mice, probably by means of an improvement in 
tumor oxygenation. Future experimental research should point out whether the 
correction of anemia by erythropoietin has the same effect. If this should turn out 
to be true, the weight loss-reducing effect of anemia reduction should be tested in 
humans in order to find the optimal hemoglobin concentration. Meanwhile, 
changes in weight loss should be taken into account in present human studies on 
erythropoietin treatment and quality of life. 
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Eicosa Pentanoeic Acid (EPA) has also shown to decrease cancer-induced 
weight loss, but EPO and EPA have not been combined so far. Further studies 
should elucidate the influence of this combination on cancer-induced weight loss. 
Our study underlined the importance of gluconeogenesis in the cancer cachexia 
cascade. The administration of an undegradable glucose-derivative could inhibit 
gluconeogenesis and ameliorate weight loss. On the other hand, such an 
intervention may lead to an accumulation of lactic acid and further experimental 
research on this topic is needed. 
Another clinical aspect of anemia is its possible influence on the efficacy of 
chemotherapy 
It is well known that quite a few cytostatic agents require a reductive or an 
oxidative step in order to become active. This means that the oxygenation status 
of the tumor is of great importance for the cytotoxicity of such agents. The 
influence of anemia and tumor hypoxia on the efficacy of the cytostatic agents 





In chapters 1 and 2 an introduction to and an outline of the thesis are given. 
Colorectal cancer is one of the most common cancers in the Netherlands and 
worldwide. In the present thesis the results of various investigations with respect 
to this disease are described, concerning: 
Epidemiology and diagnosis, prognostic factors, pulmonary metastasectomy, late 
small bowel damage due to radiation therapy and palliative chemotherapy 
Furthermore, in this thesis a murine cancer cachexia experiment is reported. The 
results are put into a broader perspective of cancer cachexia, a disorder 
characterized by involuntary weight loss and tissue wasting, which occurs in the 
majority of cancer patients, including those with colorectal cancer. 
Chapter 3 contains a general overview of colorectal cancer epidemiology, 
staging, prognostic factors and treatment anno 2003. One of the conclusions is 
that at present, postoperative adjuvant chemotherapy is only advocated for 
patients with Dukes C colon cancer, as there is no proven survival gain for 
patients with Dukes Β cancer. If one is able to identify Dukes Β colorectal cancer 
patients at highest risk of recurrence, the benefit of adjuvant chemotherapy could 
be evaluated in this subgroup. This is the rationale of the study presented in 
chapter 4. 
In this chapter the results of a case-control study which was performed to 
evaluate whether Dukes Β cancer patients with a high risk of metastases could be 
identified by certain histological and/or immunohistochemical tumor features are 
described. It appeared that the absence of Thymidine Phosphorylase expression 
( TP, this substance was formerly known as Platelet-derived Endothelian Cell 
Growth Factor) was related with a significantly lower risk of distant metastases. 
Like Vascular Endothelial Growth Factor, TP is supposed to mediate its effects 
through enhanced angiogenesis. However, we did not find a relation between 
degree of TP-expression and tumor vessel density. The risk of metastases was 
also lower in case of a delineated tumor growth pattern when compared to tumors 
with an expanding growth pattern. With these two factors a subgroup of patients 
who did not develop distant metastases could be identified. It is very worthwhile to 
evaluate the prognostic value of these tests in future studies, as they may 
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subsequently lead to implications for treatment. The kappa-values of both tests 
were moderate, but the inter-observer variation can probably be improved by 
training. 
In chapter 5 the results of a retrospective study among patients operated on 
because of late radiation enteritis of the small bowel are discussed. Radiation 
enteritis is caused by radiation damage to the local vasculature which 
subsequently results in bowel ischemia. Ischemia may lead to surgical 
complications, such as bowel perforation. The study comprised 46 patients who 
had been operated on in the Netherlands Cancer Institute in Amsterdam in the 
period between 1974 and 1990. 
Complication rate and survival were not influenced by the type of operative 
procedure performed. In most cases bowel adhesions were solved by 
adhesiolysis and or bypass, whereas patients with a bowel perforation underwent 
resection of the affected segment. Apparently, the type of surgical complication 
dictated the type of surgical solution. Preoperative hypalbuminemia and previous 
laparotomies both enhanced complication risk in an independent manner. 
Previous incomplete resection of the primary tumor and an interval between 
radiation therapy and operation shorter than 12 months both independently 
contributed to a poorer survival. 
In Chapter 6 the results of another retrospective study which has been 
performed to evaluate the benefit of metastasectomy in case of isolated 
pulmonary metastases from colorectal cancer are described. From the National 
Database for Pathology ( PALGA) we obtained anonimized pathology data on 
patients who had undergone pulmonary metastasectomy somewhere in the 
Netherlands in the period between 1982 and 1992. We requested their surgeons 
to fill in a specified enquiry list. In this way data on 38 patients ( operated on in 12 
hospitals) could be collected. At the time of evaluation 20 patients had tumor 
recurrence and in the majority of patients ( 75%) metastases were located outside 
the lungs. 
Disease-free interval was negatively influenced by the number of metastases 
resected. Patients with at least 4 pulmonary metastases had a significantly higher 
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recurrence rate than patients with 3 or less metastases ( 0% disease-free after 
two years versus almost 50%). A negative influence on overall survival was 
however not found. 
The interval between resection of the primary tumor and pulmonary 
metastasectomy was a strong prognostic indicator of overall survival. In case of 
an interval of at least 36 months the 5-years survival percentage was almost 80%. 
Apparently, isolated pulmonary metastases are not as isolated as they seem to 
be in case of a shorter time lag between primary operation and discovery of 
metastases. 
In Chapter 7 the topic of first line palliative chemotherapy in advanced 
colorectal cancer is presented. In the eighties, palliative chemotherapy was not 
considered to improve survival and treatment was limited to a selected group of 
patients. In the early nineties, several studies showed a survival benefit and 
upfront palliative chemotherapy was generally introduced. 
We performed a single-center case-control study to measure the survival impact 
of the MAYO-clinics-regimen, which consisted of 5-fluorouracil/leucovorin bolus-
injections on day 1-5 every four weeks. Before the introduction of the oral 
fluoropyrimidines this schedule was most often applied in the treatment of 
advanced colorectal cancer. 
It appeared that median survival was 11 months for patients who had received 
chemotherapy and 8 months for non-treated patients, which compares well to 
other publications on this subject. 
In the beginning of the nineties ( before the introduction of irinotecan and 
oxaliplatin), there was no generally accepted second line chemotherapy schedule 
and research mainly focussed on finding the most effective way of 5-fluorouracil-
administration and on finding the most potent modulator of its cytotoxicity. 
Modulators tested were interferon-α, methotrexate, leucovorin and N-
phosphonacetyl-L-aspartic acid ( PALA). Patients referred to the University 
Medical Center Nijmegen for palliative chemotherapy were usually included in 
randomized prospective trials which tested the benefit of infusional 5-FU in 
combination with one of its modulators. In case of progression some of these 
188 
patients were given second line chemotherapy with the same dosage of infusional 
5-fluorouracil, but with a different modulator ( modulator-rotation). 
In Chapter 8 the effect of modulator-rotation is described. Out of 66 patients, 28 
received second line treatment with another modulator. Fourteen patients ( 50%) 
had stable disease and one patient (4%) achieved a complete response. Since 
the introduction of the oral fluoropyrimidines, irinotecan and oxaliplatin the 
indication field for modulator-rotation has however diminished. 
From preclinical data it is well known that anemia causes tumor hypoxia and that 
this may subsequently lead to angiogenesis and tumor extension. In studies on 
patients with head and neck cancer or cancer of the uterine cervix overall survival 
has been shown to be poorer in case of preoperative anemia. In Chapter 9 a 
random set of patients with operable rectal cancer for which the prognostic value 
of preoperative anemia was investigated, is reported. For patients with colonic 
cancer no relation between preoperative anemia and survival was found. 
However, preoperative anemia appeared to be a negative independent prognostic 
indicator of survival in patients with operable rectal cancer. 
Cancer cachexia, defined as involuntary weight loss and tissue wasting due to 
cancer, occurs in the majority of cancer patients and seriously inflicts 
performance status and quality of life. In chapter 10 current knowledge 
regarding its etiology and treatment is reviewed. 
In chapter 11 the central role of poor tumor oxygenation in the etiology of 
cancer cachexia is explained. In case of lack of oxygen, anaerobic glucose 
dissimilation is the sole energy source. Glucose dissimilation costs much more 
energy than the energy it provides, which is explained in depth in this chapter. 
In chapter 12 the results are described of an animal experiment which was 
based on the following hypothesis: "If cancer cachexia is negatively affected by 
tumor hypoxia, reversal of hypoxia should attenuate weight loss." In this 
experiment BALB/c-mice with a cachexia-inducing tumor were either or not 
treated with recombinant human erythropoietin ( RhEPO) in combination with 
different inspiratory oxygen concentrations. RhEPO-treated mice displayed less 
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weight loss, probably due to improved tumor oxygenation mediated by a rise in 
the hemoglobin concentration. 





In hoofdstuk 1 wordt de theoretische onderbouwing van het proefschrift 
beschreven. In hoofdstuk 2 komt de indeling van het proefschrift aan bod. 
Het colorectaal carcinoom is ëën van de meest voorkomende kwaadaardige 
ziekten in Nederland en wereldwijd. In dit proefschrift komen verscheidene 
onderzoeken over deze ziekte aan de orde, die betrekking hebben op: 
Epidemiologie en diagnose, prognostische factoren, operatieve verwijdering in 
geval van geïsoleerde uitzaaiingen in de longen, radiatie-enteritis van de dunne 
darm en palliatieve chemotherapie. 
Voorts worden in dit proefschrift de resultaten van een murine cachexie-
experiment besproken. De resultaten worden vervolgens geplaatst in het bredere 
kader van kanker-cachexie, een aandoening die bij de meeste kankerpatiënten in 
de eindfase optreedt en wordt gekarakteriseerd door onvrijwillig gewichtsverlies 
en spieratrofie. 
In hoofdstuk 3 wordt een overzicht gegeven van de stand van zaken rond de 
behandeling van het colorectaal carcinoom anno 2003. Momenteel is 
postoperatieve adjuvante chemotherapie voorbehouden aan patiënten met een 
Dukes C coloncarcinoom, aangezien er geen bewezen overlevingsvoordeel van 
deze behandeling is gezien bij patiënten met een Dukes Β coloncarcinoom. De 
waarde van adjuvante chemotherapie bij het rectumcarcinoom is het 
aandachtspunt van studies die momenteel nog lopen. 
Het zou uitermate zinvol zijn indien men aan de hand van tumoreigenschappen 
kon vaststellen welke Dukes B-carcinomen wèl en welke niet metastaseren. Met 
deze kennis zou vervolgens kunnen worden onderzocht of een "hoge risico-
groep" van Dukes B-carcinoom-patiënten wel baat heeft van adjuvante 
chemotherapie. Deze gedachte vormde de basis voor de studie die in 
hoofdstuk 4 is beschreven. 
Door middel van een case-control-onderzoek werd gekeken of patiënten met een 
Dukes Β carcinoom van colon of rectum en een hoog metastaserings-risico van 
de overigen konden worden onderscheiden op basis van histologische of 
immunohistochemische kenmerken. Carcinomen die geen thymidine 
Phosphorylase ( TP) tot expressie brachten bleken significant minder vaak te 
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metastaseren. Van TP wordt verondersteld dat de stof zijn invloed op het 
metastaserings-risico uitoefent door zijn stimulerende invloed op de 
vaatnieuwvorming, net zoals Vascular Endothelial Growth Factor. We vonden 
echter geen relatie tussen TP-expressie en de mate van tumor-vascularisatie. 
Verder stelden we vast dat de metastaseringskans aanmerkelijk kleiner was als 
de tumor expansief groeide in plaats van infiltratief. Met behulp van de twee 
genoemde factoren kon een subgroep van patiënten worden gedefinieerd, die 
geen metastasen ontwikkelde. 
Het is derhalve zeer de moeite waard om de prognostische waarde van deze 
factoren te evalueren in toekomstige prospectieve studies, aangezien ze 
tezijnertijd tot consequenties voor therapie-keuze zouden kunnen leiden. De inter-
observer-variatie bij de beoordeling op deze factoren was beperkt en kan met 
training zeker nog verder worden verbeterd. 
In geval van bekken-bestraling, zoals deze bijvoorbeeld in aanvulling aan een 
verrichte rectumamputatie plaatsvindt, krijgen dunne darmlissen die in het cavum 
van Douglas zijn gelegen nogal eens een te hoge dosis radioactieve straling te 
verwerken. Beschadiging van de vasculatuur kan aanleiding geven tot late 
radiatie-enteritis en dit ziektebeeld gaf - zeker in het verleden- nogal eens 
aanleiding tot beeld van een acute buik. In hoofdstuk 5 wordt een patiënten-
groep ( n= 46) beschreven die over een tijdsbestek van 2 decennia in het 
Nederlands Kanker Instituut te Amsterdam werd geopereerd in verband met de 
gevolgen van late radiatie-enteritis van de dunne darm. 
De belangrijkste bevinding was dat het type interventie geen invloed had op het 
complicatie-risico of de overleving. Darmadhesies werden meestal behandeld 
door middel van adhesiolyse en/of bypasses en perforaties door resectie van het 
aangedane segment. Een verlaagd preoperatief serumalbumine-gehalte en 
eventuele eerdere buikoperaties waren onafhankelijke negatieve prognostische 
factoren voor wat betreft het complicatie-risico. Irradicale tumorresectie en een 
interval tussen bestraling en complicatie-chirurgie korter dan 12 maanden waren 
onafhankelijke prognostische factoren voor wat betreft de overleving. 
Indien uitzaaiingen van het colorectaal carcinoom beperkt zijn tot de longen, dient 
operatieve verwijdering te worden overwogen. In hoofdstuk 6 worden de 
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resultaten gerapporteerd van een landelijk retrospectief onderzoek onder 
patiënten die in de periode 1982-1992 een dergelijke operatie hadden ondergaan. 
Stichting PALGA, een organisatie die alle Nederlandse Pathologie-verslagen 
registreert, voorzag ons van alle uitslagen van longbiopten met de diagnose 
"métastase colorectaal carcinoom", waarbij alleen de geboortedatum van de 
patiënt en de naam van de chirurg werden vermeld. Op deze wijze konden we de 
chirurgen benaderen met het verzoek om een vragenlijst over de desbetreffende 
patiënt in te vullen. Uiteindelijk beschikten we over de complete gegevens van 38 
patiënten, die in 12 verschillende ziekenhuizen waren geopereerd. Op het tijdstip 
van evaluatie hadden 20 van de 38 patiënten reeds een tumorrecidief en in 75% 
van de gevallen was dit recidief buiten de long gelokaliseerd. 
Het ziektevrije interval werd in negatieve zin beïnvloed door het aantal 
verwijderde metastasen. In geval van 4 of meer metastasen was de recidiefkans 
significant hoger dan in geval van minder metastasen ( 0% ziektevrij na 2 jaar 
versus bijna 50%), doch er werd geen invloed op de overleving gezien. 
Het interval tussen de primaire operatie en het ontdekken van de longmetastasen 
was van sterke prognostische waarde voor wat betreft de overleving. Bij patiënten 
met een interval van tenminste 36 maanden bedroeg het 5 jaars-
overlevingspercentage bijna 80%. Bij kortere intervallen lag dit percentage onder 
40%. Dit verschil berust waarschijnlijk op een hogere kans op nog niet 
gedetecteerde metastasen elders in de long of in andere organen. 
In hoofdstuk 7 komt het onderwerp van eerstelijns chemotherapie in geval van 
een gemetastaseerd colorectaal carcinoom aan de orde. In de tachtiger jaren 
werd verondersteld dat palliatieve chemotherapie geen levensverlengend effect 
had en alleen fitte patiënten met symptomatische metastasen kregen 
chemotherapie met als doel klachten-verlichting.In het begin van de jaren 
negentig verschenen publicaties van enige kleinere onderzoeken, waarin een 
levensverlengend effect van chemotherapie was gevonden. Vanaf dat moment 
waren prospectieve onderzoeken met een controle-arm zonder chemotherapie uit 
den boze. De vraagstelling van ons onderzoek was hoe groot de mediane 
levensverlenging was in geval van palliatieve chemotherapie. Daartoe werd een 
database gevormd van de gegevens van alle patiënten die in de periode 1988-
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1997 in het Sint Joseph Ziekenhuis waren geholpen in verband met een 
colorectaal carcinoom. Uit deze database werden twee groepen patiënten 
geselecteerd, ten eerste alle patiënten die sedert 1994 eerstelijns chemotherapie 
hadden ondergaan. In die periode werden alle patiënten met een redelijke 
klinische conditie en een behandelwens behandeld met het MAYO clinics schema 
( 5-fluorouracil/leucovorin bolus-infusie gedurende 5 dagen, eenmaal per 4 
weken). Ten tweede werd een gematchte groep controles geselecteerd uit een 
periode (1984-1989), waarin chemotherapie nog niet werd toegepast. Het bleek 
dat de mediane overleving 11 maanden bedroeg voor patiënten die palliatieve 
chemotherapie hadden ondergaan en 8 maanden voor onbehandelde controles, 
hetgeen in overeenstemming was met eerdere publicaties. 
In de jaren negentig ( vòòr de introductie van irinotecan en oxaliplatin) bestond er 
geen algemeen geaccepteerd tweedelijns chemotherapie-schema en klinisch 
onderzoek spitste zich met name toe op het vinden van de meest effectieve 
toedieningswijze van 5-fluorouracil ( 5-FU) en de meest effectieve modulator van 
5-FU-cytotoxiciteit. Voorbeelden van dergelijke modulatoren zijn leucovorin, 
interferon-α, methotrexaat en N-fosfoacetyl-L-aspartaamzuur ( PALA). Patiënten 
die naar het UMC St. Radboud waren verwezen voor palliatieve chemotherapie 
werden in die periode gewoonlijk behandeld in het kader van prospectieve 
gerandomiseerde onderzoeken, waarbij de behandeling bestond uit de continue 
toediening van 5-FU in combinatie met een modulator. In geval van ziekte-
progressie werd de 5-FU vaak gecontinueerd, maar in combinatie met een 
andere modulator ( modulator-rotatie). In hoofdstuk 8 wordt de patiënten-
populatie uit het UMC St. Radboud beschreven die een dergelijke modulator-
rotatie had ondergaan. Op tweedelijns-chemotherapie hadden 14 van de 28 
patiënten stabiele ziekte ( 50%) en ëën patiënt had een complete respons. Sinds 
de introductie van orale fluoropyrimidines, irinotecan en oxaliplatin is het indicatie-
gebied voor modulator-rotatie kleiner geworden. 
Uit preklinisch onderzoek is bekend dat anemie aanleiding geeft tot tumor-
hypoxie en dat tumorhypoxie vervolgens tot angiogenese kan leiden. Studies bij 
patiënten met een hoofd/halstumor of cervixcarcinoom bevestigen dat 
preoperatieve anemie van negatieve invloed kan zijn op de overleving. In 
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hoofdstuk 9 wordt een random patiëntenpopulatie met een operabel 
rectumcarcinoom beschreven, waarin de prognostische waarde van een 
verlaagde preoperatieve hemoglobine-concentratie werd onderzocht. Patiënten 
met een operabel rectumcarcinoom en preoperatieve anemie bleken significant 
korter te leven dan de patiënten zonder anemie. 
Kanker cachexie - onvrijwillig gewichtsverlies ten gevolge van kanker - treedt bij 
de meerderheid van de kankerpatiënten in de loop van hun ziekte op en leidt in 
de regel tot een verminderde conditie en kleinere actieradius. In hoofdstuk 10 
wordt een overzicht gegeven van de huidige inzichten in de etiologie en 
behandeling van kanker cachexie. 
In hoofdstuk 11 wordt een lans gebroken voor de centrale rol van tumor-
hypoxie bij het optreden van gewichtsverlies bij kanker. Bij zuurstof-gebrek zal het 
kankergezwel zijn benodigde energie hoofdzakelijk uit de anaerobe dissimilatie 
van glucose moeten halen. Toegelicht wordt hoe dit onrendabele proces tot 
gewichtsverlies leidt. 
In hoofdstuk 12 worden de resultaten beschreven van een muizen-experiment, 
welke was gebaseerd op de volgende hypothese:"als kanker cachexie wordt 
bevorderd door tumor-hypoxie, dan kan dit worden afgeremd door een 
verbetering van de tumor-oxygenatie". Vrouwelijke BALB/c-muizen met een 
gewichtsverlies-bevorderende tumor werden wèl of niet behandeld met 
recombinant humaan erythropoietine ( RhEPO) in combinatie met verscheidene 
inspiratoire zuurstof-concentraties. RhEPO leek de mate van gewichtverlies te 
verminderen, mogelijk door de stijging van de hemoglobine-concentratie en de 
daaruitvolgende verbetering in de zuurstoftoevoer naar de tumor. 
In hoofdstuk 13 wordt een beeld geschetst van toekomstig wetenschappelijk 
onderzoek bij patiënten met darmkanker. Bovendien worden aanbevelingen 





Aan de volgende mensen ben ik dank verschuldigd. 
Geachte heer Zoetmulder, beste Frans, dankzij jou werd me de 
mogelijkheid geboden om in het Antoni van Leeuwenhoek Huis onderzoek te 
doen en rond te kijken in de kliniek. De twee artikelen die we samen schreven 
hebben beide een plaats gevonden in dit proefschrift. 
Geachte mevrouw Taal, beste Babs, ook jij hebt me geleerd dat status-
onderzoek uiterst nuttig kan zijn. 
Geachte heer Vreugdenhil, beste Ard, toen ik met mijn opleiding in 
Veldhoven begon, hielp je me om richting te geven aan het onderzoek dat tot mijn 
promotie zou gaan leiden. Je bracht me in contact met professor Dr. D.J.Th. 
Wagener en Dr. J.W.W. Coebergh en legde als zodanig een solide basis voor het 
verdere beloop. Je deed dit op een moment dat het hymenoptera-onderzoek in 
Amersfoort helaas doodbloedde. Zonder jouw enthousiasme en ijzeren discipline 
zou het promoveren veel en veel moeilijker zijn geworden. 
Geachte heer Coebergh, beste Jan-Willem, dankzij jou had ik toegang tot 
de waardevolle bestanden van het IKZ en leerde ik het nodige over 
epidemiologie. Bedankt voor je coaching bij het onderzoek en je kritische blik op 
de vervaardigde manuscripten. 
Geachte heer Peters, beste Herman, we hebben flink wat tijd achter de 
microscoop doorgebracht, je uitgeleende microscoop en pathologie-boek bleek ik 
onlangs tot mijn schrik nog steeds in mijn bezit te hebben, ik zal ze meenemen 
naar mijn promotie-feest. Kom je ze halen? 
Geachte professor van Krieken, beste Han, heel hartelijk dank voor alle 
tijd die je in me hebt geïnvesteerd. Helaas is er in twee proefballonnetjes ( P53-
expressie in levermetastasen en responskans; Ki-67-expressie in Dukes Β 
tumoren en prognose) voor jou behoorlijk veel tijd gaan zitten, die zich niet 
terugbetaalde in artikelen. Dankzij jou en Herman heb ik nu echter veel meer oog 
voor histologie en immunohistochemie en ondervind daar als oncoloog bijna 
dagelijks voordeel van. 
Geachte heer Bongaerts, beste Ger, professor Wagener heeft er heel 
goed aan gedaan toen hij mij bij jou introduceerde. Jij, biochemicus en medisch 
microbioloog, had een uiterst frisse kijk op oncologische processen, zoals kanker 
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cachexie. Ik hoop dat we ook in de toekomst zullen doorgaan met kruisbestuiving. 
Samen met professor Wagener heb jij me uitstekend geholpen om mijn 
proefschrift definitief vorm te geven. 
Beste Gerrie Grutters, Henny Eikholt en Bianca Lemmens, jullie waren 
van onschatbare waarde voor het welslagen van de murine kankercachexie-
experimenten. Heel hartelijk dank voor jullie hulp en constructieve ideeën. 
Geachte heer Van der Tier, beste Olaf, dankzij jouw uitgebreide 
computerkennis en hulp heeft het proefschrift op de juiste wijze zijn richting naar 
de drukker gevonden. Hartelijk dank voor je inspanningen. 
Geachte professor Wagener, beste Theo, ik wil je van harte bedanken 
voor je wijze lessen in de kliniek en bij het onderzoek. Als ik je zou moeten 
typeren, dan kan ik me het beste vinden in de Franse betiteling "eminence grise." 
Bescheiden, creatief en slim, bedachtzaam, een goede coach, een goede prater, 
veel humor. Ik stel het zeer op prijs dat je tijdens je emeritaat zoveel tijd bleef 
stoppen in de begeleiding van mijn werk. Ik zou willen voorstellen om een 
bijzondere leerstoel aan de Katholieke Universiteit Nijmegen te creëren voor een 
internist-antiquair. 
Lieve pappa en mamma, heel veel dank voor een warme opvoeding, 
dankzij jullie ben ik in staat geweest om te leren en te studeren zonder financiële 
zorgen, zodat er ook nog tijd voor andere dingen over bleef. 
Lieve Simone, jij hebt de grootste veer moeten laten, zonder jouw steun 
waren mijn doelen, internist worden en promoveren, misschien wel nooit bereikt. 
199 
Curriculum Vitae 
Henk van Halteren werd op 12 augustus 1965 in Hilversum geboren en bezocht 
in de periode 1977- 1983 het Comenius College te Hilversum. Aanvankelijk zou 
hij weg- en waterbouwkunde ( genie) gaan studeren aan de Koninklijke Militaire 
Academie, doch na de introductie in Breda rezen de nodige twijfels. Gelukkig 
lootte hij ook in voor de studie Geneeskunde aan de Universiteit van Amsterdam. 
Na 4 jaar ( 1987) behaalde hij zijn doktoraal examen. De wachttijd voor de co-
assistentschappen ( ruim 12 maanden) benutte hij als sabattical year. Na 6 
maanden werken, reisde hij 6 maanden low budget door India, Nepal, Thailand 
en Indonesië. Het was een heel fijne periode, doch het kostte de nodige moeite 
om tijdens de co-assistentschappen weer op stoom te komen. Het basisarts-
examen werd in januari 1991 behaald. Nadien werkte Henk bijna twee jaar in het 
Antoni van Leeuwenhoek Huis, de eerste 18 maanden in het kader van de 
vervangende dienstplicht, later als assistent-geneeskundige- niet in opleiding ( 
AGNIO). In 1993 en 1994 werkte Henk als AGNIO Interne Geneeskunde in 
Streekziekenhuis Eemland te Amersfoort, Van 1995 tot 1 juli 2000 volgde hij de 
opleiding tot internist binnen het cluster Nijmegen ( opleider Professor J.W.M, van 
der Meer). In de periode van 1 juli 1999 tot 1 januari 2001 behaalde hij zijn 
registratie voor het aandachtsgebied Medische Oncologie ( opleider Professor Dr. 
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Stellingen: 
1. Het verhogen van de eigen bijdrage voor medicatie treft de oudere relatief 
weinig vermogende patiënt het hardst: het onvermogen om de benodigde 
medicatie te betalen zal in de toekomst van doorslaggevend belang zijn voor 
de inname-trouw en niet het bijwerkingen-profiel. 
2. Het groeipatroon van een Dukes Β colorectaal adenocarcinoom vertoont een 
onafhankelijke significante relatie met metastaserings-kans ( dit proefschift). 
3. leder Nederlands ziekenhuis zou een ziekenhuis in de derde wereld moeten 
adopteren voor de uitwisseling van materiële en immateriële zaken. 
4. Voor wat betreft de overleving van geopereerde patiënten met een Dukes Α, Β 
of C rectumcarcinoom is preoperatieve anemie een onafhankelijke 
prognostische variabele ( dit proefschrift). 
5. Tumorhypoxie speelt een belangrijke rol in de etiologie van gewichtsverlies 
door kanker ( dit proefschrift). 
6. Er moet één landelijke ziektekostenverzekering komen, waarbij de poliskosten 
worden geïndexeerd aan de hand van inkomen en niet aan de hand van risico-
profiel. 
7. Bij BALB/c-muizen met een C26-B adenocarcinoom is sprake van een 
positieve correlatie tussen tumorgrootte enerzijds en lactaatspiegel/mate van 
gewichtsverlies anderzijds ( dit proefschrift). 
8. Bij BALB/c-muizen met een C26-B adenocarcinoom leidt behandeling met 
epoëtine-alpha tot stijging van de hemoglobine-spiegel. Bovendien is deze 
behandeling geassocieerd met een vermindering van gewichtsverlies. Dit is 
mogelijk te verklaren door een verbetering in tumor-oxygenatie ( dit 
proefschrift). 
9. Nader onderzoek moet uitwijzen of de verbetering van quality of life van 
kankerpatiënten na behandeling met erythropoïetine ten dele kan worden 
verklaard door een vermindering van gewichtsverlies ( dit proefschrift). 
10. De mogelijkheid van metastasectomie dient in geval van geïsoleerde 
longmetastasen van een colorectaal carcinoom ten allen tijde te worden 
overwogen ( dit proefschrift). 



